



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 1/02, 1/04, 1/107, 5/12, 7/64	A1	(11) International Publication Number: WO 00/18790 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/AU99/00813 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: PP 5164 25 September 1998 (25.09.98) AU (71) Applicant (for all designated States except US): THE UNIVERSITY OF QUEENSLAND [AU/AU]; Brisbane, QLD 4072 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): SMYTHE, Mark, Leslie [AU/AU]; 8 Morgan Terrace, Bardon, QLD 4065 (AU). MEUTERMANS, Wim, Denis, Frans [BE/AU]; 16 Fleming Road, Herston, QLD 4006 (AU). BOURNE, Gregory, Thomas [AU/AU]; 3 Rabaul Street, Moorooka, QLD 4105 (AU). MCGEARY, Ross, Peter [AU/AU]; 130 Highland Terrace, St Lucia, QLD 4067 (AU). (74) Agent: GRIFFITH HACK; P.O. Box 1285K, Melbourne, VIC 3001 (AU).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SYNTHESIS OF CYCLIC PEPTIDES (57) Abstract <p>This invention relates to methods for preparing cyclic peptides and peptidomimetic compounds in solution and bound to solid supports, and to cyclic peptide or peptidomimetic libraries for use in drug screening programmes. In particular the invention relates to a generic strategy for synthesis of cyclic peptides or peptidomimetics which enables the efficient synthesis under mild conditions of a wide variety of desired compounds. We have examined two approaches: 1) Positioning reversible <i>N</i>-amide substituents in the sequence. 2) Applying native ligation chemistry in an intramolecular sense. We have evaluated these for their improvements in the solution and solid phase synthesis of small cyclic peptides. We have systematically investigated the effects of preorganising peptides prior to cyclisation by using peptide cyclisation auxiliaries, and have developed new linkers to aid cyclic peptide synthesis. We have found surprising improvements in both yields and purity of products compared to the prior art methods. The combination of these technologies provides a powerful generic approach for the solution and solid phase synthesis of small cyclic peptides. We have also developed linkers and peptide cyclisation auxiliaries to aid cyclic peptide synthesis. The ring contraction and <i>N</i>-amide substitution technology of the invention provide improved methods for the synthesis of cyclic peptides and peptidomimetics. When used in conjunction with linker strategies, this combination provides solid-phase avenues to cyclic peptides and peptidomimetics.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SYNTHESIS OF CYCLIC PEPTIDES

This invention relates to methods for preparing cyclic peptides and peptidomimetics in solution and bound to solid supports, and to cyclic peptide or peptidomimetic libraries for use in drug screening programmes. In particular the invention relates to a generic strategy for synthesis of cyclic peptides or peptidomimetics which enables the efficient synthesis under mild conditions of a wide variety of desired compounds.

BACKGROUND OF THE INVENTION

Although the development of recombinant DNA technology and the identification and isolation of proteins mediating a wide variety of biological activities has enabled the development of new drug therapies, proteins in general suffer from the disadvantage of susceptibility to breakdown by digestive and other enzymes. This means not only that these agents usually have to be administered by injection, but that they also have a short half-life in the body.

The biological activities of a protein rely on the three-dimensional structure of the protein molecule, which results predominantly from a balance between a variety of different non-covalent interactions. In an attempt to improve the stability and acceptability of protein pharmaceuticals, both relatively short peptide sequences encompassing the active site of the protein and synthetic molecules which adopt a three-dimensional structure resembling the active site have been extensively investigated. Structurally-constrained peptides in which a framework is maintained by disulphide bonds as well as by non-covalent interactions, and cyclic peptide or peptidomimetic systems in which the cyclisation provides the structural constraint, provide two particularly attractive approaches to stabilisation of these molecules.

Cyclic peptides show a wide variety of potent biological activities. They have been extensively explored in the drug development process as a means of introducing conformational constraints for the evaluation of the structural, conformational and dynamic properties that are critical to biological activity. Some cyclic peptides are useful as drugs in their own right. Others have been engineered to provide a multitude of functions, including novel biological properties, platforms for the development of protein mimetics, nanotechnology, specific metal coordination sites, and catalysts, to name a few.

Cyclisation may be accomplished by disulfide bond formation between two side chain functional groups, amide or ester bond formation between one side chain functional group and the backbone α -amino or carboxyl function, amide or ester bond formation between two side chain functional groups, or amide bond formation between the backbone α -amino and carboxyl functions.

The potential utility of this class of compound in any application is hindered by difficulties in synthesising the compounds. Whilst the synthesis of the linear precursors generally proceeds in high yield and purity, the final cyclisation reaction can be troublesome, resulting in low yields and/or impure products. This is particularly so for cyclic peptides of fewer than seven amino acid residues, with synthesis of cyclic tetrapeptides resulting in little or no cyclic material.

These cyclisation reactions have been traditionally carried out at high dilution in solution. With the advent of orthogonal protection strategies and new resins for solid phase peptide synthesis, cyclisation has been accomplished while the peptide is attached to the resin. One of the most common ways of synthesising cyclic peptides on a solid support is by attaching the side chain of an amino acid to the resin. Using appropriate orthogonal protection strategies, the C- and N-termini can be selectively deprotected and cyclised on the resin after

chain assembly. This strategy is widely used, and is compatible with either *tert*-butyloxycarbonyl (Boc) or 9-fluorenylmethoxycarbonyl (Fmoc) protocols. However, it is restricted to peptides that contain appropriate side chain
 5 functionality to attach to the solid support. It is therefore not amenable to the combinatorial synthesis of arrays of cyclic peptides.


A number of approaches have been used in an attempt to achieve efficient synthesis of cyclic peptides.

10

LINKERS

a) Activated Linkers

One procedure for synthesising cyclic peptides is based on cyclisation with simultaneous cleavage from the
 15 resin. After an appropriate peptide sequence is assembled by solid phase synthesis on the resin or a linear sequence is appended to resin, the deprotected amino group can react mildly with its anchoring active linkage to produce protected cyclic peptides, as shown schematically in
 20 Scheme 1.



25

Scheme 1,






Solid phase cyclic peptide synthesis with activated linkers

Various linkers that have been used for the synthesis of cyclic peptides, or are amenable to their
 30 synthesis, are shown in Table 1.

Table 1

Examples of Activated Linkers Amendable
to Solid Phase Cyclic Peptide Synthesis

5

Linker	Reference
	Fridkin et al, 1965; Fridkin et al, 1968
	Osapay and Taylor, 1990; Osapay et al, 1990
	Rivaille et al, 1980
	Richter et al, 1994
	Fridkin et al, 1972; Laufer et al, 1968.

R = Peptide ,  = support

These cleavage-by-cyclisation strategies produce protected cyclic peptides, necessitating a final deprotection step to synthesise the target cyclic material. The cyclisation reaction is generally slow and low in yield, because extended conformational preference of the linear analogue impedes the final cyclisation reaction.

b) Safety Catch Linkers

Extensions of these concepts include supports that can be selectively modified at the end of the assembly to increase the lability of the linker. These linkers are stable during peptide assembly, and are selectively activated, leading to cyclisation and cleavage from the resin. In general, a final deprotection step is required to yield the target cyclic peptide. Examples of linkers that can be used for this approach are shown in Table 2.

Table 2
Examples of Safety Catch Linkers for Solid Phase Peptide Synthesis















Safety Catch	Reagent	Activated Linker	Ref.
	H ₂ O ₂		Flanigan and Marshall, 1970
	mCPBA/Dioxane		Marshall and Liener, 1970
	H ₂ O ₂		Flanigan, 1971
	HBr		Flanigan, 1971


Table 2 (cont.)

	CH ₂ N ₂		Kenner et al, 1971
	ICH ₂ CN		Backes et al, 1996
	CH ₂ N ₂		Backes and Ellman, 1994

These strategies are again limited by the conformational preferences of the linear precursor.

c) Backbone Linkers

5 A simple extension of the concept of attaching the side chain to resin to achieve C- to N-cyclisation is the attachment of the backbone N to resin. Recently Jensen et al (1996) reported a backbone linker that has been used for synthesising linear peptides, diketopiperazines, 10 peptide aldehydes and cyclic peptides (Jensen et al, 1998). There are several limitations to this process, these include difficulties in acylating the secondary amine to form the 'linked' amide bond and the fact that standard Fmoc SPPS leads to almost complete diketopiperazine 15 formation at the dipeptide stage. Special protection strategies need to be employed to avoid this problem.



20


Scheme 2

Backbone linkers for solid phase peptide synthesis

Intraresin Chain Transfer

25 Another approach for synthesising cyclic peptides involves the attachment of a linker that contains two peptide attachment points to the resin, one of which is temporarily masked. Using standard solid phase techniques, the linear precursor is assembled on resin. The X and Y 30 functionalities (Scheme 3) are then selectively unmasked and cyclised. Cleavage at the linker liberates the free C-terminal carboxylic acid group while the peptide is still attached to the resin. C- and N-cyclisation is then

achieved by standard activation conditions, yielding cyclic peptides.



5

Scheme 3

Linker combination for solid phase peptide synthesis

This method is somewhat limited by the incorporation of the appropriate functionality X into a peptide sequence, and the complex deprotection strategies required. Once again, due to the extended nature of the linear precursors, cyclisation yields would be low.

15 **Preorganising Peptides for Cyclisation**

a) *Reversible N-substitution*

The formation of a peptide ring, like any other cyclisation reaction, requires the generation of mutually reactive chain ends, and the reaction of these ends under conditions favouring intramolecular processes. The ease of formation of the ring is related to the conformational stability of the ring and to the losses of internal degrees of freedom that occur upon ring formation. Consequently the presence of turn-inducing amino acids such as Gly, Pro or a D-amino acid enhances the conformational stability of the ring and improves cyclisation yields. For linear peptides that do not contain amino acid residues that stabilise turn structures, the cyclisation reaction is

likely to be an inherently improbable or slow process, due to the preference for extended conformations resulting in large strain upon ring formation.

This has led to the utilisation of various reversible chemical modifications of the peptide main chain, to enhance the *cis* amide bond conformation and hence reduce ring strain upon cyclisation, and to improve cyclisation yields. In the synthesis of cyclo-[Phe Phe Phe Phe], each amide N was substituted with a Boc (Cavelier-Frontin et al, 1993). In this instance the cyclisation yield increased from less than 1% to 27%. Similarly, the use of the *N*-(2-hydroxy-4-methoxybenzyl) (HMB) group as a reversible *N*-substituent has resulted in similar increases in yields of cyclic peptides (Ehrlich et al, 1996; Ehrlich et al, 1996), although no systematic study has been undertaken to quantify these effects. From the point of view of constructing peptide libraries it is impracticable to substitute every amide N of the linear precursor.


20

b) Ring Contraction

Ring contraction chemistry can be used for initial formation of larger flexible rings where the desired C- and N-termini are appropriately positioned to "snap shut" in a ring contraction reaction to yield the target cyclic peptide after deprotection. Ring contraction for the synthesis of cyclic peptides by intramolecular thiazolidine formation from linear unprotected peptide precursors (Scheme 4) has recently been reported (Botti et al, 1996). This procedure has the disadvantage of incorporation of the thiazolidine ring, and an additional stereo centre, into every sequence, and is not a generic procedure suitable for a combinatorial library approach.

30

11



Scheme 4

Ring contraction chemistry for synthesis of cyclic peptides

5

Several other research groups have also utilised ring contraction approaches for the synthesis of cyclic peptides (Camamero and Muir, 1997; Shao et al, 1998). These procedures either require the presence of a Cys or are restricted to cyclisation of peptides containing Gly at one of the termini, and are therefore not suitable for library development.

There is therefore a great need in the art for a mild, efficient, versatile synthetic strategy for the synthesis of cyclic peptides. We have now found that by introducing substituents or other moieties which preorganise peptides for cyclisation, cyclic peptides can be efficiently synthesized under mild conditions both in solution and on resin. These moieties, which we have termed *peptide cyclisation auxiliaries*, result in increased yields and purity of cyclic peptides. We have examined two approaches:

1. Positioning reversible *N*-amide substituents in the sequence.
2. Applying native ligation chemistry in an intramolecular sense.

We have evaluated these for their improvements in the solution and solid phase synthesis of small cyclic peptides.

We have systematically investigated the effects of preorganising peptides prior to cyclisation, and have developed new linkers to aid cyclic peptide synthesis. We have found surprising improvements in both yields and

purity of products compared to the prior art methods. The combination of these technologies provides a powerful generic approach for the solution and solid phase synthesis of small cyclic peptides.


5 We have also developed linkers, and peptide cyclisation auxiliaries to aid cyclic peptide synthesis.

The ring contraction and *N*-amide substitution technology of the invention used in conjunction with the activated, safety catch, and backbone linker strategies of
10 the invention provide improved methods for the solid-phase synthesis of cyclic peptides.

SUMMARY OF THE INVENTION


A feature of this invention is the combination of
15 inducing flexibility in the peptide backbone, through reversible or irreversible *N*-substitution or forcing *cis* amide bond conformations via *cis*-amide bond surrogates, with novel ring contraction chemistry to preorganise peptides and facilitate the cyclisation reaction in
20 solution. Another feature of the invention is the option of combining one or more of these preorganising technologies with novel linkers which provide attachment between peptide and resin, to provide a solid phase strategy for the mild, efficient synthesis of cyclic
25 peptides or cyclic peptide libraries.

In its most preferred general aspect, this invention provides solution and solid-phase methods for the preparation of a cyclic peptide of the structure:




30

General Formula I




where is a cyclic peptide or peptidomimetic, in which the representation of the structure follows standard conventions with the C-terminus on the right hand side of P. It comprises between 1 to 15 monomers, preferably 1 to 10 monomers, more preferably 1 to 5 monomers. This may be a monocycle, bicycle or higher order cycle, and may comprise protected or unprotected monomers.

Another general aspect of the invention provides solid-phase methods for the synthesis of cyclic peptides or peptidomimetics of the structure:



15

General Formula II

where L is a linker unit, linking the cyclic peptide to the solid support . The linker L may be attached to any atom of the peptide, but is preferably attached to a backbone nitrogen or to an atom in the side chain of the monomer.

Thus, in a first aspect the invention provides a method of synthesis of cyclic peptides or cyclic peptidomimetic compounds, comprising the steps of:

- a) inducing flexibility in the peptide or peptidomimetic compound by reversible N-substitution or by forcing a cis amide bond conformation using a cis-amide bond surrogate to facilitate cyclisation, and
- b) subjecting the cyclic peptide or peptidomimetic compound to a ring contraction reaction.


This ring contraction reaction may occur spontaneously, so that a separate reaction may not be required.

The method is applicable to both solution phase and solid phase synthesis.

5

In a preferred embodiment, this aspect of the invention provides a method for solution phase synthesis of a cyclic peptide of General Formula I, comprising the steps of:

- 10 a) Preparing a linear peptide of General Formula III



15

General Formula III

where P is a linear peptide of 10 to 15 monomers, preferably 1 to 10 monomers, most preferably 1 to 5 monomers.


- 20 A1 is one or more N-substituents, either reversible or non-reversible, on the peptide backbone, or is a chemical moiety that forces a *cis* conformation of the backbone, and

- 25 A2 is a covalently-bonded group of atoms comprising a reactive functionality to form an initial large cyclic peptide prior to ring contraction to the desired substituted cyclic peptide;

- b) Activating the C-terminus to form a cyclic peptide of General Formula IV:

30


15



General Formula IV

- 5 c) Permitting the peptide of General Formula IV to rearrange via a ring contraction reaction (which may occur spontaneously) to form a cyclic peptide of General Formula V; and optionally

10




General Formula V

- 15 d) Subjecting the cyclic peptide of General Formula V to a deprotection reaction to remove the groups A1 and A2 to yield the desired cyclic peptide of General Formula I.


20 Optionally one or more of the groups A1 or A2 may be left attached to the peptide to provide a suitable point for attaching to a solid support, for derivatising with additional chemical functionality to improve library diversity, or for dimerisation or oligomerisation with other cyclic peptides or molecules, as illustrated below.

25

16



R = solid support or other chemical moiety



5


Alternatively ring contraction may lead to spontaneous elimination of A2.

Preferably A1 is a reversible N-substituent, such as 2-hydroxy-4-methoxybenzyl, 2-hydroxybenzyl or 2-hydroxy-6-nitrobenzyl substituents.

Preferably A2 comprises a nucleophile (eg. thiol or hydroxyl) that reacts rapidly with a C-terminus to form an initial large ring, which then contracts either spontaneously, or upon heating or additional chemical treatment (eg. addition of metal ions). A2 may be an irreversible substituent, may be removed after ring contraction, or may eliminate spontaneously, upon ring contraction. A2 also provides access to an additional site for substitution to increase library diversity. A2 may also be any of the compounds of General Formula I described in our co-pending PCT application corresponding to Australian provisional patent application No. PP6165 filed on 25 September 1998, the same day as this application, entitled "Auxiliaries for Amide Bond Formation". Specific examples of these auxiliaries are exemplified herein.

In a second aspect, the invention provides a method of solid phase synthesis of cyclic peptides, comprising the steps of:

a) synthesis of a linear peptide of General Formula VI, bound to a solid support via a linker L,



5

General Formula VI

where A1 and P are as defined above and L is a linker between any atom of the peptide and the solid support, and


10

(b) either

(i) subjecting the peptide (comprising either protected or unprotected monomers) to cyclisation and concomitant cleavage from the solid support to yield a

15

cyclic peptide of General Formula VII,



General Formula VII


20

followed by selective removal or derivatisation of A1 as described above, if necessary followed by side chain deprotection of the peptide and removal of A1 to yield the desired cyclic peptide of General Formula I; or

25

(ii) cyclisation of the peptide to yield a second solid support-bound cyclic peptide of General Formula VIII,

18




General Formula VIII

5 The person skilled in the art will appreciate that side chain deprotection of the peptide, removal of A1 and cleavage from the solid support may be performed separately or concurrently. Removal of peptide protecting groups, A1 and cleavage from the solid support will yield
10 the desired cyclic peptide of General Formula I.

Alternatively both a linker unit and A2 as described above are used.

Thus in another preferred embodiment, the invention provides a method of solid-phase synthesis of a
15 cyclic peptide, comprising the steps of:

a) preparing a linear solid support-bound peptide of General Formula IX:




20

General Formula IX

in which A2, P and L are as defined above;


b) subjecting the peptide of General Formula
25 IX to cyclisation and concomitant cleavage from the solid support to yield a cyclic peptide of General Formula X;

19



General Formula X

- 5 c) allowing the cyclic peptide X to undergo ring contraction (which may occur spontaneously) to yield a second cyclic peptide of General Formula XI, and




10

General Formula XI

- d) either derivatising the group A2, or removing A2 to yield the desired cyclic peptide of General
15 Formula I.

In another alternative the linear solid support-bound peptide of General Formula IX may be subjected to initial cyclisation and ring contraction on the solid support to yield a solid support-bound cyclic peptide of
20 General Formula XII,



General Formula XII

25

and either

(i) cleaved from the solid support to yield an A2- substituted cyclic peptide, or

(ii) deprotected and cleaved from the solid support to yield a cyclic peptide of General Formula I.

5 Alternatively, the group A2 may be derivatised either in solid phase or in solution.

Again it will be appreciated that peptide deprotection, removal of A2 and cleavage from the solid support may be performed separately or concurrently.

10 Most preferably the method of the invention utilises all three of


(i) N-substituents,

(ii) a covalently-bonded group of atoms which forms an initial large ring which subsequently contracts, and
15

(iii) synthesis on a solid support.

Therefore in a third aspect, the invention provides a method of solid phase synthesis of a cyclic peptide, comprising the steps of

20 a) synthesis of a linear solid support-bound peptide of General Formula XIII,




25

General Formula XIII

where A1, A2, P and L are as defined above;

b) subjecting the peptide of General
30 Formula XIII to cyclisation and concomitant cleavage from the solid support to yield a cyclic peptide of General Formula XIV,

21



General Formula XIV


5 c) subjecting the cyclic peptide of General Formula XIV to ring contraction (which may be spontaneous), and

 d) cleaving the groups A1 and A2 to yield the desired cyclic peptide of General Formula I.

10 Alternatively this aspect of the invention provides a method of solid phase synthesis of cyclic peptides, comprising the steps of;

 a) synthesis of a linear solid support-bound peptide of General Formula XIII,

15 b) subjecting the linear peptide to cyclisation on the solid support to yield a cyclic peptide of General Formula XV,




20

General Formula XV

 c) subjecting the cyclic peptide to ring contraction (which may occur spontaneously) to yield a
25 cyclic peptide of General Formula XVI,


22



General Formula XVI

5 and either

d) cleaving groups A1 and A2 while the peptide is bound to the solid support to yield a solid support-bound cyclic peptide of General Formula II, or



10

General Formula II

e) subjecting the cyclic peptide to
 15 deprotection and concomitant cleavage from the solid support to yield the desired cyclic peptide of General Formula I.

Once again it will be appreciated that peptide deprotection, removal of A2 and cleavage from the solid
 20 support may be performed separately or concurrently.

For the purposes of this specification, the term "monomer" includes compounds which have an amino and carboxy terminus separated in a 1,2, 1,3, 1,4 or larger substitution pattern. This includes the 20 naturally-
 25 occurring α -amino acids in either the L or D configuration, the biosynthetically-available amino acids not usually found in proteins, such as 4-hydroxy-proline, 5-

hydroxylysine, citrulline and ornithine; synthetically-derived α -amino acids, such as α -methylalanine, norleucine, norvaline, C α - and N-alkylated amino acids, homocysteine, and homoserine; and many others as known to the art. It also includes compounds that have an amine and carboxyl functional group separated in a 1,3 or larger substitution pattern, such as β -alanine, γ -amino butyric acid, Freidinger lactam (Freidinger et al, 1982), the bicyclic dipeptide (BTD) (Freidinger et al, 1982; Nagai and Sato, 1985), amino-methyl benzoic acid (Smythe and von Itzstein, 1994), and others well known to the art. Statine-like isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres and other amide bond isosteres known to the art are also useful for the purposes of the invention. Thus the word "peptide" as used herein encompasses peptidomimetic compounds. Optionally the peptide may be protected with one or more protecting groups of the type used in the art (see for example Bodanszky, M., (1984), *"Principles of Peptide Synthesis"*, Springer-Verlag, Heidelberg).

A peptide is comprised of between one and fifteen monomers, preferably between one and ten monomers, more preferably one to five monomers.

The solid support may be of any type used for solid phase synthesis of peptides, peptidomimetics, oligonucleotides, oligosacharides or organic molecules. The solid support may be in the form of a bead, a pin or another such surface which is suitable for use in solid phase synthesis. A wide variety of suitable support materials are known in the art. See for example Meldal, M., *Methods in Enzymology*, 1997 289 83-104. Commercially-available polystyrene supports, including aminomethyl-polystyrene, benzhydrylaminepolystyrene, polyethyleneglycol-polystyrene are especially suitable.


A "linker" means any covalently-bonded group of atoms which connects an atom or molecular fragment to

another via covalent bonds. See for example Songster, M.F., Barany, G., *Methods in Enzymology*, 1997 289 126-175.

Typically the linker will comprise an optionally substituted allyl, aryl, alkylene group containing

5 functionality, such as an ether, ester, amide, sulfonamide, sulfide, or sulfoxide functionality, within the linker. Such a functionality will normally be used to create the connection between the two groups, or to separate the groups.

10 A "cis amide bond surrogate" is a chemical group, such as a tetrazole (Marshall et al, 1981), which forces a cis conformation.



15

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

20 Coupling methods to form peptide bonds are well known to the art. See for example Albericio and Carpino, 1997. When synthesising cyclic peptides in solution or upon a side chain or backbone attachment, the choice of activation can affect the yields and purity of cyclic
25 material. For slow cyclisations the increased lifetime of the intermediate activated linear peptide provides an opportunity for increased epimerisation at the C-terminal residue. The extent of epimerisation may be diminished by application of the azide method (Izumiya et al, 1981) or
30 its modification using DPPA (Brady et al, 1983). However, these methods are extremely slow, usually requiring many hours or even several days (Izumiya et al, 1981; Schmidt and Neubert, 1991; Heavner et al, 1991). In comparison with DPPA, TBTU (Knorr et al, 1989) and BOP (Castro et al,

1975) provide fast cyclisation, but may lead to C-terminal epimerisation. The HOAt coupling reagents have recently been reported significantly to improve head-to-tail cyclisation of penta- and hexa-peptides with reduced epimerisation rates (Ehrlich et al, 1996).

Brief Description of the Figures

Figure 1 shows HPLC elution profiles of the crude product of solid phase synthesis of cyclo-D-G-(Cat)-R-G following cyclisation and concomitant cleavage from the resin (Profile A) and HPLC-purified cyclo-D-G-(Cat)-R-G synthesised in solution phase (Profile B).

Figure 2 shows an LC-MS profile of the crude filtrate obtained after HF cleavage and base cyclisation of a cyclic peptide synthesised using a safety catch linker of n=2.

Figure 3 shows the results of HPLC analysis of cyclisation of linear peptide 1a A) after 3h at rt, and B) 1h heating to 65°C in the presence of excess DIEA. The solutions were dried under high vacuum, dissolved in 50% aqueous acetonitrile and were loaded directly onto a Vydac reversed-phase C-18 (5 µm, 300 Å, 0.46 x 25 cm) HPLC column. The products were separated using a linear 0-80% buffer B gradient over 40 min at a flow rate of 1 mL/min.

Figure 4 shows the results of HPLC analysis of the photolysis of cyclic peptide 8a at timed intervals. A 0.15mM solution of peptide 8a in MeOH / 1% AcOH was photolysed using a standard UV lamp, and at different time intervals small aliquots were injected onto a Zorbax reversed-phase C-18 (3 µm, 300 Å, 0.21 x 5 cm) HPLC column. The products were separated using a linear 0-80% buffer B gradient over 10 min at a flow rate of 200 µL/min (detection at 214 nm).

Figure 5 shows the HPLC profile of the reaction products from cyclisation of peptides 1a, 1d and 1e, (i)

1eq BOP , 2eq DIEA, 1mM in DMF; (ii) 10 eq DIEA, 6h at rt.
L=Linear peptide, Cycl = head-to-tail cyclic product.

Figure 6 shows an HPLC comparison of the crude
5 cyclisation products of peptide 1f using either HATU or BOP
as cyclisation reagent. The two major peaks in the
chromatograms have a molecular weight of 825g/mol,
corresponding to the target cyclic product cyclo-[(Hnb)Gly-
(Hnb)Tyr-Arg-Phe]. The first eluting product is the all-L
10 isomer, the second product contains D-Phe.

Figure 7 shows the reaction profiles obtained
from cyclisation of peptide 4 under a range of reaction
conditions.

Figure 8 shows results of crude HPLC of linear peptides
15 17 and 18 using backbone linkage. A = H-Tyr-Arg-Phe-Gly-OH
17; B = [Hnb]Tyr-Arg-Phe-Gly-OH 18; Cleavage was performed
using HF : p-cresol, 9 : 1, -5 °C, 1 h.

Figure 9 shows the results of crude HPLC for the
cyclisation of linear peptides 16 using backbone linkage.
20 A = [Hnb]Tyr-Arg-Phe-Gly-OH 18; B = cyclo-[[Hnb]Tyr-Arg-
Phe-Gly] 21. Cyclisation was performed using BOP, DIEA, 3
days, while cleavage was performed using HF : p-cresol, 9
: 1, -5 °C, 1 h.

Figure 10 shows the effect of compounds (1µM) on
25 evoked excitatory junction currents (measure of transmitter
release) from sympathetic varicosities of the mouse vas
deferens. Each filled circle represents an EJC recorded
during 100 minutes. Failure to record an EJC is indicated
by filled circles on zero of the y-axis. The lower
30 horizontal line indicates when the mixture of cyclic
tetrapeptides (1µM) was applied to the tissue bathing
solution and the upper horizontal line when naloxone (1µM)
was added to the tissue bathing solution. Note that the
mixture of tetrapeptides (1µM) greatly reduces the EJC
35 amplitude and frequency, and that the opiate antagonist
(naloxone) inhibits this effect.

Figure 11 shows the effect of a mixture of cyclic tetrapeptides (1 μ M) on the average excitatory junction current (EJC) recorded from sympathetic varicosities of mouse vas deferens. Each bar is the average of at least 60 recordings, and the vertical lines show the standard deviation of the mean. Note there was a highly significant decrease in EJC amplitude and frequency following 20 minutes of cyclic tetrapeptide exposure of the preparation, and that this effect was reversed by naloxone.

DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail by way of reference only to the following non-limiting examples, and to the figures.

Abbreviations used herein are as follows:

DIEA	Diisopropylethylamine
DMF	dimethylformamide
DMSO	dimethylsulphoxide
DPPA	diphenylphosphoryl azide
BOP	benzotrizo-1-yloxy-tris(dimethylamino) phosphonium hexafluorophosphate
HOAt	7-aza-1-hydroxybenzotriazole
HBTU	O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate
HMB	2-hydroxy-4-methoxybenzyl
HPLC	high performance liquid chromatography
ISMS	ion spray mass spectrometry
LC-MS	liquid chromatography-mass spectrometry
NMR	Nuclear Magnetic Resonance
ROESY	rotating frame Overhauser enhancement spectroscopy
r.t.	room temperature
TOCSY	total correlated spectroscopy.

Experimental

General Methods

Melting Points were determined on a Gallenkamp m.p. apparatus and are uncorrected. Solvent evaporation were carried out using a Büchi rotary evaporator. Deionised water was used throughout, and was prepared by a Milli-Q water purification system (Millipore-Waters). Screw-cap glass peptide synthesis reaction vessels (20 mL) with sintered glass filter frit were obtained from Embell Scientific Glassware (Queensland, Australia). An all-Kel-F apparatus (Peptide Institute) was used for HF cleavage. Argon, helium and nitrogen (all ultrapure grade) were from BOC gases (Queensland, Australia).

^1H NMR spectra were recorded on a Varian Gemini 300 spectrometer at 300 MHz, and chemical shifts are reported in δ parts per million down field from tetramethylsilane. Coupling constants (J) refer to vicinal proton-proton coupling. ^{13}C NMR spectra were also recorded on a Varian Gemini spectrometer at 75.5 MHz. TOCSY and ROESY spectra were performed on a Büchi ARX 500 spectrometer.

Mass spectra were acquired on a PE-Sciex API-III triple quadrupole mass spectrometer equipped with an Ionspray atmospheric pressure ionization source. Samples (10 mL) were injected into a moving solvent (30 mL/min; 50/50 $\text{CH}_3\text{CN}/0.05\%$ TFA) coupled directly to the ionisation source via a fused silica capillary interface (50 mm i.d. x 50 cm length). Sample droplets were ionized at a positive potential of 5 kV and entered the analyser through an interface plate and subsequently through an orifice (100-120 mm diameter) at a potential of 80 V. Full scan mass spectra were acquired over the mass range of 200 to 1000 daltons with a scan step size of 0.1 Da. Molecular masses were derived from the observed m/z values using the MacSpec 3.3 and Biomultiview 1.2 software packages (PE-Sciex Toronto, Canada).


Thin layer chromatography (Tlc) was performed on silica gel 60 F₂₅₄ plates (Merck Art 5735). The chromatograms were viewed under u.v. light and/or developed with iodine vapour. Preparative column chromatography was effected under pressure, using for normal phase Merck Kieselgel 60 (Merck Art 7734). Analytical reverse phase - HPLC were run using a C-18 Vydac column (218TP52022), while Semi-Preparative reverse phase HPLC was carried out using a C-18 Vydac column (218TP52022). Both columns were attached to a Waters HPLC apparatus fitted with a Holochrome U.V. detector. Measurements were carried out at either $\lambda=214$ nm or 254 nm. Chromatographic separations were achieved using linear gradients of buffer B in A (A = 0.1 % aqueous TFA; B = 90 % CH₃CN, 10 % H₂O, 0.09 % TFA) at a flow rate of 0.25 mL/min (microbore), 1 mL/min (analytical) and 8 mL/min (preparative).

Materials

Boc-L-amino acids, Fmoc-L-aminoacids, Boc-Val-Polyaminomethylstyrene Resin, Merrifield resin, Boc-Gly-PAM Resin, synthesis grade dimethylformamide (DMF), trifluoroacetic acid (TFA) and diisopropylethylamine (DIEA) were purchased from Auspep (Parkville, Australia) or Novabiochem (Alexandria, Australia). Chlorotriyl Resin was purchased from Pepchem (Tubingen, Germany). HBTU and BOP were purchased from Richelieu Biotechnologies (Montreal, Canada). Tris(2-carboxyethyl)phosphine hydrochloride salt (TCEP) was purchased from Strem Chemicals Inc. Newburyport MA. AR grade EtOAc, MeOH, CH₂Cl₂, CHCl₃, hexane, acetone and HPLC grade CH₃CN were all obtained from Laboratory Supply (Australia), HF was purchased from CIG (Australia). All other reagents were AR grade or better, and were obtained from Aldrich or Fluka.

Example 1 Peptide Cyclisation Auxiliaries**Backbone substitution**

N-substitution has the potential to alter the *cis-trans* equilibrium favouring more *cis* conformations and enhancing cyclisation yields:



We have examined the effect of the number and position of *N*-methylations on cyclisation yield of tetraglycine. Eight linear tetrapeptides were synthesised, including all permutations of glycine and sarcosine (*N*-methyl glycine) at the three C-terminal residues. These are summarised in Table 3.

Table 3

Linear *N*-substituted Tetraglycines and
Corresponding Yields of Cyclisation

5	<u>Linear tetrapeptide</u>	<u>Yield of cyclisation</u>
	Gly-Gly-Gly-Gly	<1%
	Gly-Gly-Gly-Sar	8%
	Gly-Gly-Sar-Gly	11%
10	Gly-Sar-Gly-Gly	1%
	Gly-Gly-Sar-Sar	18%
	Gly-Sar-Gly-Sar	2%
	Gly-Sar-Sar-Gly	13% (16%*)
	Gly-Sar-Sar-Sar	~5%

15

* Yield of cyclisation for the corresponding *N*-HMB substituted linear tetraglycine, ie where sarcosine is replaced by [-N(HMB)-CH₂-CO-].


20

The yield for each cyclisation was calculated from the weight of isolated product. The results of this experiment suggest that *N*-substitution of the *N*-1 or *N*-2 position of a tetrapeptide significantly improves yields of cyclisation whereas *N*-substitution at the third residue has little effect. The effect of multiple substitution at two or more *N*-sites appears to be more or less additive. The best cyclisation result was obtained with the *N*-1 and *N*-2 substituted precursor Gly-Gly-Sar-Sar. However, from a synthetic point of view substitution at the *N*-1 position is less desirable, as this facilitates diketopiperazine formation at the dipeptide stage during assembly of the linear precursor. We have found that altering the position of the backbone substituent can significantly affect the ratio of monocycle over dimer or higher oligomers.

35

We have extended this *N*-substitution approach to include reversible *N*-substitution. Three linear

precursors, the backbone unprotected peptide X and two backbone HMB-substituted analogues Y and Z, were prepared.



The three peptides were subjected to standard cyclisation protocols and the crude reaction mixtures analysed by HPLC and ISMS. The products (monomers and dimers) were further examined for epimerisation at the C-terminal leucine. Table 4 lists the products found and the corresponding yield of isolated material (% by weight).

Table 4
Yields of Isolated products from Cyclisation
of Tetrapeptides X, Y and Z

	X	Y	Z
Linear	—	10%	—
Monocycle (L-Leu)	—	8%	7%
Monocycle (D-Leu)	—	2%	16%
Dimer (L,D-Leu)	1%	—	8%
Dimer (L,L-Leu)	17%	19%	15%
Overall % D	3%	5%	43%

As expected, the unsubstituted tetrapeptide X generates dimers, with no detectable amounts of monocycle present as assessed by ISMS. Two dimers are found in a ratio of 1/10 as assessed by HPLC. The first eluting dimer

contains L-Leucine and D-Leucine in a ratio of 1/1. The second eluting dimer is formed from cyclisation of the all L-octapeptide. Considering that for cyclisation of peptide X, 0.5% D-Leu is observed and that a total yield of 18% was achieved, this equates to an overall epimerisation at the C-terminus of approximately 3% ($0.5/18 \times 100$).

On the other hand, both backbone-substituted tetrapeptides Y and Z generate a significant amount of cyclic tetrapeptide (monocycle), corroborating the N-Me study described above. As for peptide X, two dimers are formed [L-Leu/D-Leu and L-Leu/L-Leu] when cyclising peptide Y. For tetrapeptide Y a total of 80% of the separated monocycle contains L-Leu, but surprisingly for tetrapeptide Z a total of 70% of the separated monocycle contains D-Leu. For peptide Y about 5% D-Leucine is found in the total separated product, and for peptide Z 43% D-Leu is found. For tetrapeptide Z, this is equivalent to almost 100% racemisation (50% D-Leu : 50% L-Leu). In an attempt to minimise epimerisation of the C-terminus, cyclisation of tetrapeptide Z was performed with HATU instead of BOP. Under these conditions overall % D-leucine was halved.

Once epimerised, tetrapeptide Z cyclises more efficiently (16% D-Leu monocycle, no D-Leu/D-Leu dimer detected). Tetrapeptide Y is less reactive, as significant amounts of linear peptide are still present after three hours of activation. This may be explained by increased steric hindrance at the N-terminus.

We conclude that introduction of an HMB group on the middle amide nitrogen of the tetrapeptide X (ie. tetrapeptide Z) assists cyclisation, but significantly promotes epimerisation of the C-terminus. Substitution at the third amide nitrogen (tetrapeptide Y) assists cyclisation without increased epimerisation but reduces the reactivity of the peptide. In Example 3 below, we describe ring contraction chemistry that may help alleviate the epimerisation problems while enhancing cyclisation through N-substitution.

Experimental to Example 1

This section describes the experimental details for preorganising peptides prior to cyclisation via N-substitution.

Date in Table 3

Boc-Sar-Merrifield resin was prepared as follows: Boc-Sar-OH (380 mg, 2 mmole) was dissolved in 2 mL H₂O containing Cs₂CO₃ (326 mg, 1 mmole). The mixture was lyophilised and residue taken up in DMF (5 mL). The solution is added to Merrifield resin (2.7 gr, 0.7 mmol/gr) and heated to 50°C overnight. The resin is filtered, washed and dried (3.05 gr, 0.65 mmole/gr). The tetrapeptides were assembled using *in situ* neutralisation protocols. After assembly the peptides were cleaved using HF/p-cresol (9/1) at 0°C for 1 hour. The HF was then evaporated and the product precipitated with cold ether (10 mL). After the ether washes (3 x 10 mL) the crude peptides were dissolved in water and purified by HPLC using 100% water (0.1%TFA).

Cyclisation (Table 3)

The purified peptides (0.1 mmole) were dissolved in 100 mL DMF. BOP (133 mg, 0.3 mmole) was added followed by DIEA (0.5 mmole, 87 µL). After stirring overnight, the DMF was removed *in vacuo*, and the residues dissolved in acetonitrile/water (1/1) containing TFA (0.1%) and loaded on a reverse phase HPLC column. The isolated products from the HPLC run (10 minutes at 100% A, then 1% gradient to 50% B) were analysed by ISMS and analytical HPLC, dried and weighed. Yields were calculated from the weight of the isolated product.

Epimerisation Studies (Table 4)

The N-substituted linear peptides were synthesised on chloro-trityl resin. The HMB-protection

group was introduced via solid phase reductive alkylation of the N-terminus with 2-hydroxy-4-methoxybenzaldehyde (Ede et al, Tetrahedron Lett., 1996 37 9097). Acylation of the secondary amine was carried out by preactivating the
5 following Fmoc-protected residue using HOAT (2Eq.) and DIC (1Eq.) for 30 min in DMF and performing the reaction at 50°C for 12 hours. The peptide assembly was completed as described previously and linear peptide cleaved from the resin (1%TFA in DCM). All three peptides (all L-residues)
10 were purified by reverse phase HPLC prior to cyclisation.

Cyclisation


The purified peptides (0.1 mmole) were dissolved in DMF (100 mL). BOP (133 mg, 0.3 mmole) was added,
15 followed by DIEA (0.5 mmole, 87 µL). After 3 hours stirring the DMF was removed in vacuo, residues dissolved in acetonitrile/water (1/1) containing TFA (0.1%) and the solution loaded on a reverse phase HPLC column. The isolated products from the HPLC run (5 minutes at 80% A,
20 then 2% gradient to 100% B) were analysed by ISMS, analytical HPLC and epimerisation of leucine determined by amino acid analysis. Yields were calculated from the weight of the isolated product and the ratio of L/D from AA-analysis.

25

Example 2 Ring Contraction

Another approach to overcoming the problems in the solution and solid phase synthesis of small cyclic peptides is to utilise novel ring contraction chemistry.
30 As previously noted, the preferred extended conformation and rigidity of amide bonds is a problem in small peptide cyclisation. By initially forming a larger, more flexible ring, through the inclusion of a flexible "linker unit", the potential for end-to-tail cyclisation is enhanced by
35 increasing the effective concentration of the C- and N-terminus. The desired C- and N-termini are then appropriately positioned to "snap shut" in a ring


contraction reaction. This is shown schematically in Scheme 5.



5

Scheme 5
Ring contraction chemistry


The ring contraction auxiliaries illustrated
10 below are evaluated for this purpose.



Examples of ring contraction auxiliaries

15

Additional auxiliaries include:



A subset of ring contraction auxiliaries

5 To examine the feasibility of the ring contraction approach, we have synthesised a number of linear pentapeptides carrying an ethane thiol group at the N-terminus. The synthesis of the linear precursors was achieved as illustrated in Scheme 6. Bromoacetic acid was


10 coupled to the N-terminus of the resin-bound tetrapeptide using the symmetrical anhydride approach. The bromopeptide was treated with a 2M solution of cystamine in DMSO and the resulting peptide cleaved from the resin. The disulfide moiety was further reduced using TCEP in an 0.1M ammonium

15 carbonate solution and the free sulfide purified by HPLC. The sulfide was then subjected to standard cyclisation conditions (ie 10^{-3} M in DMF, 3 eq. BOP, 5 eq DIEA). Presumably, the initially formed thioester spontaneously rearranges to the ethane thiol substituted cyclic peptide.

20 The resulting product was confirmed by NMR examination and by the fact that the sulfide readily dimerises in DMF. The dimer was isolated and characterised by ISMS and NMR. Reduction of the dimer with TCEP reestablished the free

25 sulfide-peptide in quantitative yields.

38



Scheme 6

Synthesis and cyclisation of the linear ethane
thiol-substituted precursor for ring contraction

This process has several distinct advantages. The increased nucleophilicity of the thiol compared to the amine presumably results in rapid formation of the thioester, thereby significantly reducing the potential for epimerisation. The C- and N-termini are then appropriately positioned to snap shut in a ring contraction reaction.

In this example the ethane thiol group is irreversibly linked to the cyclic target. We have designed and tested other auxiliaries, outlined above, that allow cleavage of the auxiliary-peptide bond. The ring contraction in all the above-mentioned examples proceeds via a five or six-membered fused ring transition state.

Synthesis of a difficult cyclic peptide, [cyclo[Ala-Phe-Leu-Pro-Ala]]:

H-Ala-Phe-Leu-Pro-Ala-OH was a recently reported example of a sequence which is difficult to cyclise (Schmidt and
5 Langner, 1997). When subjected to cyclisation conditions, dimers and higher oligomers were generated, but no target - cyclopentapeptide was formed. In the following set of experiments, summarized in Scheme 7, we demonstrate that the monocycle was accessible using a ring contraction
10 strategy.

Cyclisation of unsubstituted Ala-Phe-Leu-Pro-Ala.

As a control experiment we attempted to cyclise the unsubstituted linear peptide (Ala-Phe-Leu-Pro-Ala) using
15 standard cyclisation conditions (1mM in DMF, 3eq. BOP, 5eq. DIEA, 3h at rt). As expected from the previously reported results (Schmidt and Langer, 1997), only cyclic dimer and some trimer were obtained, but no target monocyclic product was isolated.


20

Cyclisation using 5-nitro-2-hydroxybenzyl auxiliary.


The 5-nitro-2-hydroxybenzyl auxiliary used in this and other examples was as described in our co-pending PCT application corresponding to Australian provisional
25 application No. PP6165 filed on 25th September 1999. The peptide 1a, containing the 5-nitro-2-hydroxybenzyl substituent, was synthesised and cyclised under standard conditions, yielding two monocyclic products as well as significant amounts of a side product 3a (Mr, 812 Da),
30 caused by reaction of the phenol functionality with excess BOP in the reaction mixture (Scheme 7, A). By adjusting the amount of activating reagent and base, formation of this side product was completely avoided. The reaction conditions were further optimised by altering the
35 temperature and amount of base after an initial cyclisation period, and monitoring the formation of monocyclic products by LC/MS analysis. The best results were obtained when

after 3h of reaction (1mM in DMF, 1eq BOP, 2eq DIEA, rt) excess DIEA (10eq) was added and the mixture left standing for 24 h or heated to 65°C for 1 hour.

A.



B.



5

Scheme 7: Cyclisation of auxiliary containing peptides **1,2** (A) and formation of the target cyclic peptides **7,8** (B) ; i) 3 eq. BOP / 5 eq. DIEA, 3h at rt; ii) 1 eq. BOP / 2 eq. DIEA, 3h rt; 10 eq. DIEA, 12h rt or 1h at 65°C; iii)

10 hv (366nm).

The HPLC profile of the crude product is depicted in Figure 3B. The main product (50% isolated yield) was unambiguously characterised by NMR, ES-MS and chiral amino acid analysis as the all-L target monocyclic product **7a**. A ^1H NMR absorption at 11.5 ppm confirmed that the product contained the free hydroxy substituent, and thus did not have the ester structure but rather the target cyclic amide structure. Further, a small amount of the C-terminally racemised product **7b** (see Figure 3B) was also isolated. A

chiral amino acid analysis of the product confirmed the presence of a D-Ala residue.

5 **Cyclisation using 6-nitro-2-hydroxybenzyl auxiliary.**

As the 5-nitro-2-hydroxybenzyl auxiliary is not readily removed after cyclisation, we examined cyclisation using the 6-nitro-2-hydroxybenzyl auxiliary peptide **2a**. The *ortho*-nitro substituent, while maintaining a similar
10 activation effect on the ring contraction of the cyclic intermediate **6a** (compared to **5a**), has the added benefit that it should render the auxiliary photolabile. The linear peptide **2a** was synthesised and treated as described above for the 5-nitro-2-hydroxy derivative. Thus
15 cyclisation (at 1mM in DMF, 1 eq. BOP / 2eq. DIEA) was performed at rt for 3 h, followed by addition of excess DIEA (10eq) and heating to 65°C for 1 hour. The major product was isolated in 39% yield, and characterised by NMR and chiral amino acid analysis as the all-L cyclo-
20 pentapeptide **8a**. A small amount of the C-terminal racemised cyclic product (containing a D-Ala) **8b** was also isolated.

Similarly *N*-(6-nitro-2-hydroxybenzyl)Phe-Leu-Pro-Ala-Ala **2c**
25 was assembled and cyclised as above. The all-L cyclo pentapeptide **8c** was isolated in 45% yield.

Removal of the auxiliary. Cyclic peptide **8a** was then subjected to photolysis at 366nm, using a standard UV lamp,
30 in a range of solvent conditions. In most solvents (MeOH, MeOH/AcOH, THF/AcOH, dioxane) the nitrobenzyl substituent on the backbone nitrogen is readily removed to generate the target cyclic peptide **9a** (Scheme 5, B). Figure 4 illustrates the clean and efficient conversion (**8a** to **9a**).
35

The cyclic product was characterised by chiral amino acid analysis and ¹H NMR. The spectral data were in good

agreement with the reported data. Furthermore, an independent sample of cyclic peptide, prepared by the cyclisation of Phe-Leu-Pro-Ala-Ala according to Schmidt et al (1997), coeluted with the product obtained from
5 photolysis.

The same product 9a was obtained from photolysis of the regio analogue 8c. The racemised cyclic product 8b was photolysed, and similarly produced the unsubstituted D-Ala
10 containing product 9b, which coeluted with an independently synthesised sample.

Experimental to Example 2


This section describes the experimental details
15 of the use of ring contraction concepts for the synthesis of small cyclic peptides.

Ring Contraction

Synthesis of Ring Contraction Auxiliaries

20

N-(2-Bromoethoxy)phthalimide



25




Exact Mass: 268.97

Mol. Wt.: 270.08


N-(2-Bromoethoxy)phthalimide was synthesised by a
30 modification of the procedure of Bauer and Suresh (Bauer et al 1963). *N*-Hydroxyphthalimide (80 g, 0.49 mol), triethylamine (150 mL, 1.08 mol), and 1,2-dibromoethane (175 mL, 2.30 mol) were combined in DMF (575 mL) and

stirred at room temperature overnight. Solids were filtered and washed with DMF and the filtrate was diluted with water (4.0 L) and the resulting precipitate filtered, dissolved in EtOAc (500 mL), and washed with 1 N HCl (2 x 5 100 mL), water (1 x 100 mL), and dried over MgSO₄. Volatiles were removed in vacuo, and the resulting solid recrystallised from 95% EtOH to give (9) as a white solid (87.1 g, 70%): mp. 94-96°C; lit. mp. 94-96°C. ¹H NMR (CDCl₃): δ 7.82 (m, 4H), 4.49 (t, 2H, J = 6.9 Hz), 3.65 (t, 10 2H, J = 6.9 Hz).

N-[2-[S-(4-Methylbenzyl)thio]ethoxy]phthalimide



15



Exact Mass: 327.09


Mol. Wt.: 327.40

20 N-[2-[S-(4-Methylbenzyl)thio] ethoxy]phthalimide was synthesised by a modification of the procedure of Canne et al (Flanigan, 1971). Bromide (55.15 g 217 mmol), 4-methylbenzyl mercaptan (30 g, 217 mmol) and DIPEA (38.55 mL, 217 mmol) were combined in acetonitrile (200 mL) 25 and stirred at room temperature for 72 h. Volatiles were removed in vacuo, EtOAc (500 mL) added and filtered. Solids were washed with EtOAc, and the organics were combined and washed with 1 N HCl (2 x 200 mL), brine (1 x 200 mL) and water (1 x 200 mL) and dried over MgSO₄. 30 Volatiles were removed in vacuo and the resulting solid recrystallised from EtOAc : hexane, 1:1 to yield (10) as a white solid (50.14 g, 71%): mp. 82-84°C; ¹H NMR (CDCl₃): δ 7.80 (m, 4H), 7.18 (d, 2H, J = 8.0 Hz), 7.04 (d, 2H,

J = 8.0 Hz), 4.22 (t, 2H, J = 7.4 Hz), 3.75 (s, 2H), 2.79 (t, 2H, J = 7.4 Hz), 2.27 (s, 3H).

S-(4-Methylbenzyl)-2-(aminooxy)ethanediol

5




C₁₀H₁₅NOS

Exact Mass: 197.09

Mol. Wt.: 197.30

- 10 S-(4-Methylbenzyl)-2-(aminooxy) ethanediol was synthesised by a modification of the procedure by Osby et al (1993). The *N*-substituted phthalimide (20.0 g, 61.1 mmol) was suspended in a solution of 2-propanol (550 mL) and water (85 mL) and cooled to below 10°C. NaBH₄ (18.9 g, 252 mmol) was added portionwise so that the temperature did not exceed this temperature. The mixture was allowed to warm to room temperature and stirred overnight. Acetic acid (135 mL) was slowly added until the bubbling ceased, and the flask was stoppered and heated to 50°C for 3 h
- 15 Volatiles were removed *in vacuo*, and the resulting oil solution diluted with 1 N NaOH and extracted with EtOAc (4 x 200 mL). The hydroxylamine was then extracted into a solution of HCl (2N, 500 mL) and washed with EtOAc (2 x 250 mL). NaCO₃ was then added to the aqueous phase until
- 20 bubbling ceased, and the hydroxylamine extracted into EtOAc (3 x 250 mL). The combined organic layers were washed with H₂O (2 x 250 mL) and dried over MgSO₄. Volatiles were removed *in vacuo*, and the resulting oil purified by flash chromatography (Hexane EtOAc, 3:1) to yield as a clear
- 25 colourless oil (10.04g, 84%): ¹H NMR (CDCl₃): δ 7.21 (d, 2H, J = 8.0 Hz), 7.12 (d, 2H, J = 8.0 Hz), 5.40 (br s, 2H), 3.77 (t, 2H, J = 6.5 Hz), 2.71 (s, 2H), 2.64 (t, 2H, J = 6.5 Hz), 2.33 (s, 3H).
- 30

Application Of Ring Contraction Auxiliary (Scheme 6)

NH₂CH₂CH₂SSCH₂CH₂-Gly-Arg-Pro-Phe-Gly-OHC₂₈H₄₅N₉O₆S₂


Exact Mass: 667.29

Mol. Wt. 667.85

- 5
- 10 The peptide NH₂CH₂CH₂SSCH₂CH₂-Gly-Arg-Pro-Phe-Gly-OH was synthesised in stepwise fashion from Boc-Gly-Pam resin (0.5 g, 0.5 mmol/g) by established methods, using *in situ* neutralisation/HBTU activation protocols for Boc chemistry. The Pmc protecting group was used for the Arg
- 15 residue. Coupling reactions were monitored by quantitative ninhydrin assay and were typically >99.9%. After chain assembly was complete and the N^α-Boc group removed with neat TFA (2 x 1 min treatment) and neutralised with 10% DIEA in DMF (2 x 1 min treatment), the peptide was
- 20 bromoacetylated by the method of Robey (Robey, F.A., Fields, R.L., Anal. Biochem., 1989 177 373-377). Bromoacetic acid (277.9 mg, 2.0 mmol) was dissolved in CH₂Cl₂ (2 mL), to which was added DIC (126.2 mg, 1 mmol). After activation for 10-15 min to form the symmetric
- 25 anhydride, the mixture was diluted with DMF (2 mL), added to the peptide resin, and coupled for 30 min. The resin was washed with DMSO, and cystamine (2 M in DMF, 4 mL) was allowed to react with the bromoacetylated peptide resin for 16 h. The linear peptide was cleaved from resin by the
- 30 addition of thiocresol: cresol, 1:1 (1 mL), followed by treatment with HF (10 mL) for 1 h at -5°C. After removal of the HF under reduced pressure, the crude peptide was

precipitated in anhydrous Et₂O and filtered to remove the scavengers. The peptide was dissolved in HOAc: H₂O, 1:19, filtered and the filtrate lyophilized. NH₂CH₂CH₂SSCH₂CH₂-Gly-Arg-Pro-Phe-Gly-OH was purified by semi-preparative
 5 HPLC (20-80% B over 60 min) to give the wanted material (79.6 mg 47%) yield. MS [M+H]⁺ = 668.1 (expected 668.3).

HSCH₂CH₂-Gly-Arg-Phe-Gly-OH





Exact Mass: 592.28

Mol. Wt.: 592.71

15 The disulfide (66.8 mg, 0.10 mmol) was dissolved in a 0.03 M solution of NH₄⁺OAc⁻ (20 mL). Tris(2-carboxyethyl)phosphine hydrochloride salt (TCEP) (35.6 mg, 0.15 mmol) was added portionwise to the stirred solution at r.t. After a further 3h at this temperature
 20 the resulting mixture was lyophilized to give a white powder. The peptide HSCH₂CH₂-Gly-Arg-Phe-Gly-OH was purified by semi-preparative HPLC (20-80% B over 60 min) to yield a white powder (40.1 mg, 68%); MS [M+H]⁺ = 593.1 (expected 593.3).



25

Cyclo-(SCH₂CH₂-Gly-Arg-Pro-Phe-Gly)

Exact Mass: 574.27

Mol. Wt.: 574.70



5 The linear peptide HSCH₂CH₂-Gly-Arg-Pro-Phe-Gly-OH (40.0 mg, 0.068 mmol) and BOP (88.4 mg, 0.2 mmol) was
10 stirred in DMF (68 mL, 1x10⁻³ M) at -10°C. DIPEA (121 µL, 0.68 mmol) was added dropwise to the solution. The reaction was left to stir for a further 2 h at this temperature, before all volatiles were removed *in vacuo*.
The peptide Cyclo-(SCH₂CH₂-Gly-Arg-Pro-Phe-Gly) was
15 purified by semi-preparative HPLC (20-80% B over 60 min) to yield a white powder (12.2 mg, 31%); MS [M+H]⁺ = 743.2 (expected 743.4092).

Bis-[cyclo-Gly(CH₂CH₂S)-Arg-Pro-Phe-Gly]

Exact Mass: 1146.52

Mol. Wt.: 1147.38

5 The peptide Cyclo-(SCH₂CH₂-Gly-Arg-Pro-Phe-Gly)
 (12 mg, 0.016 mmol) was dissolved in a solution of Na₂HPO₄
 10 (0.03 M) and stirred at room temperature overnight. The
 resulting solution was lyophilized to give a white powder.
 The peptide Bis-[cyclo-Gly(CH₂CH₂S)-Arg-Pro-Phe-Gly] was
 purified by reverse phase HPLC (20-80% B over 60 min) to
 yield a white powder (7.4 mg, 81%); MS [M+2H]²⁺ = 574.22
 15 (expected 574.27).

Cyclo-(Gly(CH₂CH₂SH)-Arg-Pro-Phe-Gly)

Exact Mass: 574.27

Mol. Wt.: 574.70

5

The disulfide (7.4 mg, 6.50 μmol) was dissolved in a 0.03 M solution of $\text{NH}_4^+\text{OAc}^-$ (20 mL). TCEP (4.75 mg, 20.0 μmol) was added portionwise to the stirred solution at r.t. After a further 3h at this temperature the resulting mixture was lyophilized to give a white powder. The peptide Cyclo-(Gly(CH₂CH₂SH)-Arg-Pro-Phe-Gly) was purified by semi-preparative HPLC (20-80% B over 60 min) to yield a white powder (5.5 mg, 74%); MS $[\text{M}+\text{H}]^+ = 575.24$ (expected 575.28).

10

15

**Experimental to synthesis of cyclo [Ala Phe Leu Pro Ala]
Cyclisation experiments.**

20

25

Cyclisation of auxiliary-containing peptides 1 and 2: 1 equivalent of BOP and 2 equivalents of DIEA in DMF were added to a 1 mM solution of the linear peptide in DMF and stirred for 3 h at rt. 10 equivalents of DIEA were then added, and the solution heated at 65°C for 1 h. DMF was removed in vacuo, and the crude product was dissolved in acetonitrile/water (1:1) and purified by RP-HPLC.

Cyclisation of other linear peptides: Cyclisations were performed using a 1mM solution of linear peptide in DMF. 3 equivalents of BOP and 5 equivalents of DIEA were added,

and the solution stirred for 3 h at rt. Work-up was as described above.

5 **Cyclo-[N-(5-nitro-2-hydroxybenzyl)-Ala-Phe-Leu-Pro-Ala]**
(7a). Cyclisation of *N*-(5-nitro-2-hydroxybenzyl)-Ala-Phe--
Leu-Pro-Ala 1a (30 mg of the TFA salt, 0.038 mmol),
produced 7a (12.5 mg, 0.019 mmol) in 51% yield : ES-MS Mr
650.2, calcd for C₃₃H₄₂N₆O₈, 650.3 (monoisotopic). ¹H NMR
10 (500 MHz, DMSO-d₆, ppm) δ 11.5 (s, 1H, OH), 8.40 (d, 1H,
NH_{Leu}), 8.02 (dxd, 1H, *H*-ar), 7.70 (d, 1H, *H*-ar), 7.4 (d,
1H, HN_{Phe}), 7.20-7.30 (m, 5H, *H*-Phe), 6.99 (d, 1H, *H*-ar),
6.54 (d, 1H, *H*-NAla), 5.00 (s, 1H, ArCHhN-), 4.91 (m, 1H,
α-Ala⁵), 4.75 (q, 1H, α-Ala¹), 4.59 (m, 1H, α-Phe), 4.50
15 (m, 1H, α-Leu), 4.27 (t, 1H, α-Pro), 3.88 (d, 1H, ArCHhN-),
3.62 (m, 1H, δ-Pro), 3.37 (m, 1H, δ-Pro), 2.97 (m, 1H, β-
Phe), 2.82 (m, 1H, β-Phe), 2.04 (m, 2H, β-Pro), 1.88 (m,
1H, γ-Pro), 1.73 (m, 1H, β-Leu), 1.65 (m, 1H, γ-Pro), 1.44
(m, 1H, γ-Leu), 1.33 (m, 1H, γ-Leu), 1.24 (d, 3H, β-Ala⁵),
20 0.91 (d, 3H, β-Ala¹), 0.85 (m, 6H, δ-Leu). ¹³C NMR (75 MHz,
DMSO-d₆, ppm) 172.61, 170.34, 170.07, 169.95, 169.47,
160.40, 139.73, 136.88, 129.31, 128.14, 126.50, 125.72,
124.21, 122.65, 115.00, 61.04, 56.50, 55.74, 48.70, 46.31,
44.34, 41.37, 38.28, 31.30, 24.20, 22.81, 22.68, 21.17,
25 18.97, 15.35.

Cyclo-[N-(6-nitro-2-hydroxybenzyl)-Ala-Phe-Leu-Pro-Ala]
(8a). From cyclisation of *N*-(6-nitro-2-hydroxybenzyl)-Ala-
Phe-Leu-Pro-Ala 2a (20 mg of the TFA salt, 0.025 mmol),
30 8a (6.5 mg, 0.010 mmol) was obtained in 39% yield : ES-MS Mr
650.6, calcd for C₃₃H₄₂N₆O₈: 650.3 (monoisotopic). ¹³C NMR
(75 MHz, CD₃OD, ppm) δ 178.07, 176.95, 174.54, 174.32,
173.72, 159.11, 153.19, 140.41, 131.99, 129.96, 129.54,
127.57, 121.18, 116.57, 62.75, 60.67, 58.55, 54.05, 51.15,
35 44.54, 43.41, 34.85, 33.67, 25.03, 24.13, 22.30, 21.31,
15.49, 13.89.


Cyclo-[N-(6-nitro-2-hydroxybenzyl)-Phe-Leu-Pro-Ala-Ala] (8c). From cyclisation of the N-(6-nitro-2-hydroxybenzyl)-Phe-Leu-Pro-Ala-Ala (20 mg of the TFA salt, 0.025 mmol), **8a** (7.3 mg, 0.011 mmol) was obtained in 44% yield : ES-MS
5 Mr 650.2, calcd for C₃₃H₄₂N₆O₈: 650.3 (monoisotopic). ¹³C NMR (75 MHz, DMSO-d₆, ppm) δ 171.43, 171.00, 169.46, 167.56, 156.65, 138.43, 129.24, 129.05, 128.32, 128.18, 126.08, 119.50, 115.87, 114.60, 62.18, 60.69, 51.07, 49.38, 46.57, 45.46, 41.54, 38.17, 33.65, 31.43, 24.37, 22.73,
10 22.32, 21.06, 17.87, 16.92.

Cyclo-[Ala-Phe-Leu-Pro-Ala] (9a). a) Cyclo-[N-(6-nitro-2-hydroxybenzyl)-Ala-Phe-Leu-Pro-Ala] (1mM MeOH) was purged with nitrogen for 30 minutes and then photolysed with a
15 standard laboratory UV lamp (366nm, 0.25A) for three hours. The MeOH was evaporated and the residue dissolved in 50% buffer B, and the solution loaded directly onto a Vydac C18 column (preparative) for HPLC purification. Cyclo-[Ala-Phe-Leu-Pro-Ala] was isolated in 52% yield. The product
20 coeluted with an independently synthesised sample. ES-MS Mr 499.4, calcd for C₂₆H₃₇N₅O₅, 499.3 (monoisotopic).
b) Photolysis of purified cyclo-[N-(6-nitro-2-hydroxybenzyl)-Phe-Leu-Pro-Ala-Ala] was performed as described above. Cyclo-[Phe-Leu-Pro-Ala-Ala] was isolated
25 in 28% yield. The product coeluted with a independently synthesised sample. ES-MS Mr 499.1, calcd for C₂₆H₃₇N₅O₅, 499.3 (monoisotopic).

30 **Example 3 Backbone Substitution and Ring Contraction in Solution.**

In this example we demonstrate that cyclisation via ring contraction is significantly more facile for backbone substituted peptides than for their backbone unsubstituted analogues. We have employed the 6-nitrobenzyl-2-hydroxy
35 auxiliary both as a backbone substituent and a ring contraction auxiliary. The person skilled in the art will appreciate that the Hnb-group could readily be replaced by

many other auxiliaries, such as those described above. The general reaction scheme is as follows: Cyclisation of the disubstituted linear peptide **1** produces disubstituted head-to-tail cyclic peptide **2**. Both substituents on the backbone are then removed by photolysis to form the target cyclic peptide **3**.



Scheme 8: A combination approach: backbone substitution and ring contraction.

10

In order to evaluate the roles of ring contraction and position of the backbone substituent in the formation of cyclic tetrapeptides, we synthesised the following set of linear peptides:

15

1a. [Hnb]Tyr-Arg-Phe-Gly

1b. Tyr-[Hnb]Arg-Phe-Gly

1c. Tyr-Arg-[Hnb]Phe-Gly

20

1d. [Hnb]Tyr-[Hnb]Arg-Phe-Gly

1e. [Hnb]Tyr-Arg-[Hnb]Phe-Gly

25

All peptides were cyclised in parallel under the same conditions (either rt or 65°C), on a 1mg peptide scale. A 1mM solution of the peptide (1a-e) in DMF was treated with 1 eq. of BOP and 2 eq of DIEA. After 3 hours at rt, 10 eq DIEA was added, and stirring continued at rt for 6 h or at 65°C for 1h. The solvent was then removed, and the residue

was dissolved in acetonitrile/water and analysed by HPLC and MS.

Peptide **1a** readily underwent initial ring closure, but ring
5 contraction to the target product was slow and required
heating for extended periods (65°C / 20h). If cyclisation-
of **1a** was carried out at rt (6h) no cyclic peptide was
detected in the crude product. The control peptide **1c**
generated mainly cyclic dimer (MW: calcd for C₆₆H₇₆N₁₆O₁₆ =
10 1348.6 , exp = 1348.2) and linear dimer (MW: calcd for
C₆₆H₇₈N₁₆O₁₇ = 1366.5 (monoisotopic), exp = 1366.7) , with
only small amounts of target monocycle formed. Control
peptide **1b** under cyclisation conditions generated a complex
mixture of products.

15

In contrast, for peptides **1d** and **1e**, which contain both a
backbone substituent and a ring contraction auxiliary,
ring closure and ring contraction was almost complete under
the same mild reaction conditions (6h at rt). Figure 5
20 shows the cyclisation profiles of peptides **1a**, **1d** and **1e**
after 6h at rt. Under these mild conditions, peptide **1a** did
not undergo any significant ring contraction, and the crude
product contained largely linear peptide (L). Peptides **1d**
and **1e** on the other hand produced the target cyclic
25 peptides cyclo-[(Hnb)Tyr-(Hnb)Arg-Phe-Gly] **2d** and cyclo-
[(Hnb)Tyr-Arg-(Hnb)Phe-Gly] **2e** respectively (MW: calcd for
C₄₀H₄₃N₉O₁₁ = 825.3 (monoisotopic), exp (Cycl peptide **2d**)
= 825.1, exp (Cycl peptide **2e**) = 825.1) in excellent
purity and yield . Note that the cyclic products have the
30 same molecular weight but different substitution patterns.

These results clearly demonstrates that the N-backbone
substituent plays a vital role in facilitating the ring
contraction for highly constrained ring systems such as
35 tetrapeptides. It is also clear from this that our
combination strategy will allow access to a range of cyclic
tetrapeptides and peptidomimetics.

Large scale cyclisation of peptide **1d** (10 mg) produced the cyclic (disubstituted) product **2d** in 61% yield after HPLC isolation. Photolysis of this product (3h / DMF) generated the target cyclo-[Tyr-Arg-Phe-Gly] **3**. The overall yield after cyclisation, purification, photolysis and HPLC isolation was 28% (by weight).

Evaluating Racemisation

To examine the extent of racemisation during cyclisation we elected to synthesise and cyclise the following set of peptides:

1f. [Hnb]Gly-[Hnb]Tyr-Arg-Phe

1g. [Hnb]Gly-Tyr-[Hnb]Arg-Phe

1h. [Hnb]Gly-Tyr-Arg-[Hnb]Phe

Note that cyclisation of these peptides will generate cyclic products of different structure but the same MW. Cyclisations were initially carried out on small scale (1mg). Peptides **1f** and **1g** under our 'standard' cyclisation conditions generated two monocyclic products of the correct molecular weight. No starting material or other products were detected. The HPLC profile for peptide **1f** is shown in Figure 6.

Cyclisation of peptide **1h** on the other hand was somewhat slower, and generated mainly *D*-Phe cyclic product; the product contains 60% linear peptide.

In order to investigate racemisation further, the following combination of reagents and solvents were evaluated:

Solvent:	Dioxane or DMF.
Activating reagents :	BOP or HATU.
Base:	DIEA or Symmetric collidine.
time/temp:	20h at rt or 1h at 70°C.

A total of 16 reaction conditions were applied in parallel including all combinations of the above solvents, reagents, bases and conditions (1eq activating reagent, 2eq base, 1mM of peptide 1f in solvent). The reaction products were analysed by removing the solvent in the Genevac and resuspending the residue in acetonitrile/water, followed by HPLC analysis. Dioxane proved to be a poor solvent for the cyclisation. In most of the cases examined, only starting material could be detected. This is most likely due to the fact that the linear peptide is hardly soluble in dioxane. For the DMF experiments, HATU activation generated more L-cyclic peptide, but the effect is small (see figure 4). Changing collidine for DIEA had no effect on the product profile, with the same amount of racemisation being observed.

A large scale cyclisation was performed on peptide 1f, and two cyclic products were isolated by HPLC as a mixture in 68% yield (by weight). The two products could be separated by HPLC and photolysed to generate one unsubstituted cyclic peptide each (MW = 523 gr/mol) (non-coeluting). One of the products coeluted with the product from peptide 1d, and therefore was assigned to be the all-L cyclo-[Gly-Tyr-Arg-Phe]. The second eluting product was assigned to be the cyclo-[Gly-Tyr-Arg-(D)phe]. Photolysis of the mixture generated a mixture of the two cyclic unsubstituted peptides in 34% yield (overall yield 23%). The first product coelutes with the product obtained by cyclisation and subsequent photolysis of peptide 1d.

Combination of ring contraction and backbone substitution for the synthesis of cyclo-[Tyr-Arg-Phe-Ala] , with cyclisation at the Tyr-to-Ala site.

As mentioned in the background section of this specification, turn-inducing elements such as Gly and Pro

can favour cyclisation. Here we apply our combination technology to the synthesis of peptides that do not contain turn-inducing amino acids. In this example we employ the combination strategy (backbone substitution and ring contraction auxiliaries) for the synthesis of a very difficult target, an all-L cyclic tetrapeptide cyclo-[Tyr-Arg-Phe-Ala].

10 **4 [Hnb]Tyr-Arg-[Hnb]Phe-Ala**

Small scale (1mg peptide) cyclisation was investigated using the following conditions:

- 15 i. 1mM solution of peptide in DMF, 1 eq BOP, 2 eq DIEA, 3h at rt
- ii. addition of 10 eq. DIEA
- iii. 20h at rt ; or 1h at 70°C; or 20h at 70°C

Peptide 4 under these cyclisations conditions provided cyclic product of the correct molecular weight.

To verify whether cyclisation of peptide 4 could be improved, an optimisation was carried out, in which solvent and temperature conditions were altered in the above standard protocols:

Solvents: Temperature conditions in (iii):

DMF	20h	rt
DMSO	1h	70°C
30 Dioxane	20h	70°C
Toluene		

With dioxane or toluene as solvent, very poor yields of cyclic product were obtained at any of the temperatures used. In general, DMSO produced significantly cleaner reaction profiles when compared to DMF, as illustrated in Figure 7.

The results of the DMSO experiments can be summarised as follows:

- 5 **20h/rt:** Two main cyclic products are formed (A and B) ;
 both display the correct molecular weight in ES-
 MS (MH+ at 840 m/z).
- 1h/70°C:** Similar results, but one of the two monocyclic
 products (A) is decreased in intensity.
- 10 **20h/70°C:** Only one monocyclic product is formed (B).
 Monocyclic product (A) is not present.

 A large scale cyclisation (60 mg of linear peptide) was
 carried out in DMSO at rt (20h), and the two monocyclic
15 products were isolated by HPLC (combined yield: 46%, ratio
 is about 1/1).

 The two cyclic products were subjected to heating and to
 photolysis:

20

 Product A: Unstable to heat; the product fully decomposed
 upon heating for 20 h at 70°C in DMSO. Stable
 to hydrolysis (aqueous buffer at pH 9).
 Photolysis of this compound in DMSO proceeded
25 reasonably well; both HnB groups were removed,
 and **cyclo-[Tyr-Arg-Phe-(D)Ala]** was isolated by
 HPLC in 42% yield.
 The presence of D-Ala was confirmed by chiral
 amino acid analysis.

30 Product B: Stable to heat and to hydrolysis conditions
 aqueous buffer at pH 9).
 Photolysis did not proceed very readily.
 Chiral amino acid analysis confirmed the
 presence of L-Ala.

35 This product is the all-L cyclo-[(Hnb)Tyr-Arg-
 (Hnb)Phe-Ala].

To further assess the versatility of the combination approach, we examined cyclisation of peptide 5 under the 'normal' conditions:

- (i) 1 eq Bop, 2 eq DIEA, 1mM DMF (3h, rt);
- 5 (ii) 10 eq DIEA (12h at rt).

5. [Hnb]Ala-Tyr-[Hnb]Arg-Phe

The cyclisation at the Ala-to-Phe site was carried out on a large scale (30mg). One cyclic product, which displayed the expected molecular weight and isotope distribution pattern in ES-MS, was isolated by preparative HPLC in 53% yield.

The surprising results reported in this example illustrate the power of the combination approach for the synthesis of cyclic peptides and peptidomimetics. One skilled in the art will also realise the potential of applying this combination to the synthesis of cyclic peptides on solid supports.

20

Experimental to Example 3:

Peptide synthesis: The linear peptides 1a-e were synthesised on chlorotrityl resin (0.91mmol/g). Fmoc-Gly-OH was loaded on the resin in the manner recommended by the supplier (Pepchem). The peptides were then assembled using Fmoc-SPPS protocols. Removal of the Fmoc group was carried out by treating the Fmoc-peptide resin with 50% piperidine in DMF (2 x 2 min). Coupling of the following amino acid was carried out as follows: 4 equivalents of Fmoc amino acid was dissolved in DMF containing 4 equivalents of HBTU (0.5 M solution of HBTU). After 1 min the solution was added to the amino-peptide resin and the resin shaken for 10 min. A ninhydrin test was performed to ensure complete acylation. If acylation was not complete, the reaction mixture was left longer until ninhydrin test was negative (>99% coupling). The 2-hydroxy-6-nitrobenzyl auxiliary was attached via reductive amination, as described in Example

2. After introduction of the Hnb-group, the next residue was coupled using the same HBTU activation protocol, but coupling reaction was left at rt for 20h. The peptides were then cleaved from the resin by treatment with 95% TFA / 5%
5 water (45 min at rt). The TFA was evaporated, and the peptide precipitated with ether. The precipitate was dissolved in acetonitrile/water and loaded onto a preparative HPLC column, and a 2%/min gradient (100% A to 20% A) used to elute the products. The fractions containing
10 the target products were then combined and analysed by HPLC (purity) and ES-MS.

Peptide **1a** was isolated in 50 % yield (from the theoretical substitution value of the resin).

ES-MS: calcd for $C_{33}H_{40}N_8O_9$ = 692.3 (monoisotopic), exp =
15 692.4.

Peptide **1b** was isolated in 54% yield (from the theoretical substitution value of the resin). ES-MS: calcd for $C_{33}H_{40}N_8O_9$ = 692.3 (monoisotopic), exp = 692.2. Peptide **1c** was isolated in 25% yield (from the theoretical
20 substitution value of the resin)

ES-MS: calcd for $C_{33}H_{40}N_8O_9$ = 692.3 (monoisotopic), exp = 692.2.

Peptide **1d** was isolated in 28% yield (from the theoretical substitution value of the resin)

25 ES-MS: calcd for $C_{40}H_{45}N_9O_{12}$ = 843.3 (monoisotopic), exp = 843.2.

Peptide **1e** was isolated in 22% yield (from the theoretical substitution value of the resin)

ES-MS: calcd for $C_{40}H_{45}N_9O_{12}$ = 843.3 (monoisotopic), exp =
30 843.2.

Large scale cyclisation of peptide 1d: 0.011 mmol of linear peptide **1d** (10 mg of the TFA salt) was dissolved in DMF (5mL) containing 0.012 mmol BOP (5.2 mg). DMF (5mL)
35 containing 0.025 mmol DIEA (4.3 μ L) was added, and the mixture stirred for 3 hours (rt). 0.25 mmol DIEA (40 μ L) was added and the reaction left stirring for another 20 hours.

The solvent was evaporated under high vacuum, the residue dissolved in acetonitrile/water and loaded on a preparative HPLC column. A 1.5 % gradient was used to elute the products (100% buffer A to 20% buffer A). Cyclo-[(Hnb)Tyr-(Hnb)Arg-Phe-Gly] **2d** (5.3mg, 0.0064 mmol, 61%) was isolated: ES-MS: calcd for $C_{40}H_{43}N_9O_{11}$ = 825.3 (monoisotopic), exp = 825.1.

The product **2d** (5 mg, 6×10^{-3} mmol) was then dissolved in DMF (10mL), the solution placed in a beaker and photolysed for 3 hours using a UV lamp (350 - 365nm, 20W, Black/White/Blue). The DMF was removed under vacuum, the residue dissolved in acetonitrile/water, the solution filtered and loaded on a preparative HPLC column. A 1.5% gradient from 100%A to 20%A was used to elute the products. Cyclo-[Tyr-Arg-Phe-Gly] was isolated in 47% yield (1.5 mg, 2.8×10^{-3} mmol) : ES-MS: calcd for $C_{26}H_{33}N_7O_5$ = 523.2 (monoisotopic), exp = 523.3.

20 Evaluating Racemisation

Peptide synthesis: Peptides **1f** and **1g** were synthesised as described above. Peptide **1f** was isolated in 39% yield (from the theoretical substitution value of the resin) ES-MS: calcd for $C_{40}H_{45}N_9O_{12}$ = 843.3 (monoisotopic), exp = 842.9. Peptide **1g** was isolated in 28% yield (from the theoretical substitution value of the resin) ES-MS: calcd for $C_{40}H_{45}N_9O_{12}$ = 843.3 (monoisotopic), exp = 843.3. Peptide **1h** was synthesised on Boc-Phe-PAM resin using Boc SPPS protocols as described above, and was isolated in 28% yield (from the theoretical substitution value of the resin) ES-MS: calcd for $C_{40}H_{45}N_9O_{12}$ = 843.3 (monoisotopic), exp = 843.2.

Standard Cyclisation conditions:

- 35 i. Linear peptide at 1mM in DMF, 1eq BOP , 2 eq DIEA, 3h at rt.

- ii. Addition of 10 eq of DIEA and 20 h at rt or 1h at 70°C.

Following this the solvents were removed under vacuum, the residue dissolved in acetonitrile/water and the crude product solutions analysed by ES-MS and HPLC.

Large scale cyclisation of peptide 1f: Peptide 1f (30 mg of the TFA salt, 0.0355 mmol) was dissolved in DMF (30 mL) and 6 eq DIEA (18.3 µL) added. After addition of 1 eq BOP (17.1 mg) the reaction was stirred for 20 h. The solvent was then removed (high vacuum), the residue dissolved in acetonitrile/water and the solution loaded directly onto a preparative HPLC column. A 1.5% gradient from 100%A to 20%A was used to elute the products. The fractions containing cyclic product were collected, combined and lyophilised. 17.5 mg of a mixture of two products was obtained (68% yield): ES-MS: Calcd for C₄₀H₄₃N₉O₁₁ = 825.3 (monoisotopic), Exp = 825.1. The mixture of two products (17 mg) was dissolved in DMF (20mL) and photolysed for 3 hours. The solvent was removed, the residue dissolved in acetonitrile/water and the solution loaded onto a preparative HPLC column. A 1.5% gradient from 100%A to 20%A was used to elute the products. The target cyclic products, cyclo-[Gly-Tyr-Arg-(L)Phe] and cyclo-[Gly-Tyr-Arg-(D)Phe] were isolated as a mixture (3.8 mg, 35% yield): ES-MS: calcd for C₂₆H₃₃N₇O₅ = 523.2 (monoisotopic), Exp = 523.3. The ratio of L-Phe/D-Phe was determined by chiral amino acid analysis to be 2/3. Of the mixture of two cyclic products, the first eluting one coeluted with the all-L cyclo-[Tyr-Arg-Phe-Gly] 1d synthesised as described above.

Combination of ring contraction and backbone substitution for the synthesis of cyclo-[Tyr-Arg-Phe-Ala] , cyclisation at the Tyr-to-Ala site.

Peptide synthesis: Peptide synthesis and cleavage was performed on Fmoc-Ala-Wang resin (0.45mmol/gr) as described

above. Peptide 4b was isolated in 77% yield (from the theoretical substitution value of the resin) : ES-MS: calcd for C₄₁H₄₇N₉O₁₂: 857.9, Exp.: 857.4. Peptide 5 was isolated in 28% yield: ES-MS: calcd for C₄₁H₄₇N₉O₁₂: 857.9, exp.:

5 857.4.

Large scale cyclisation of peptide 4: Peptide 4 (60 mg of the TFA salt, 0.062 mmol) was dissolved in DMSO (60 mL) and 1 eq BOP (31.2 mg) added. 2 eq DIEA (24 µL) were added and
10 the reaction stirred at rt for 3h. 10 eq DIEA (240 µL) were added and stirring continued for another 20h.. The solvent was removed (high vacuum), the residue dissolved in acetonitrile/water and the solution loaded directly onto a preparative HPLC column. A 2% gradient from 95%A to 10%A
15 was used to elute the products. Two cyclic products were separated:

Product A (9mg, 18 %) ES-MS: calcd for C₄₁H₄₅N₉O₁₁ = 839.3 (monoisotopic), exp = 839.5. Chiral amino acid analysis of the product showed the presence of L-Tyr, L-Arg, L-Phe and D-Ala. Product A = cyclo-[(Hnb)Tyr-Arg-(Hnb)Phe-(D)Ala].
20

Product B (7mg, 13%) ES-MS: calcd for C₄₁H₄₅N₉O₁₁ = 839.3 (monoisotopic), exp = 839.5. Chiral amino acid analysis showed the presence of L-Tyr, L-Arg, L-Phe and L-Ala.
25 Product B = cyclo-[(Hnb)Tyr-Arg-(Hnb)Phe-Ala]. Another 8 mg of a mixture of products A and B (15%) was isolated, giving a total cyclisation yield of 46%.

Photolysis of cyclo-[(Hnb)Tyr-Arg-(Hnb)Phe-(D)Ala]:

30 Product A (9 mg) was dissolved in DMF (100 mL) and photolysis carried out for 3h. The solvent was removed, the residue dissolved in acetonitrile/water and the solution loaded onto a preparative HPLC column. A 1.5% gradient from 95%A to 10%A was used to elute the products.
35 The cyclic product, cyclo-[Tyr-Arg-Phe-(D)Ala] was isolated (2.4 mg, 42% yield): ES-MS: calcd for C₂₇H₃₅N₇O₅ = 537.61 (monoisotopic), exp = 537.2. Chiral amino acid analysis of


this product showed presence of L-Tyr, L-Arg, L-Phe and D-Ala.

Large scale cyclisation of peptide 4: Peptide 4 (30 mg of the TFA salt, 0.031 mmol) was dissolved in DMF (35 mL) and 1 eq BOP (15.5 mg) added. 3 eq DIEA (18.2 μ L) were added and the reaction stirred at rt for 3h. 10 eq DIEA (61 μ L) were added and stirring continued for another 20h.. The solvent was removed (high vacuum), the residue dissolved in acetonitrile/water and the solution loaded directly onto a preparative HPLC column. A 2%/min gradient from 95%A to 10%A was used to elute the products. One cyclic product was separated:

Cyclo-[(Hnb)Tyr-Arg-(Hnb)Phe-Ala]: (15.6mg, 60%) ES-MS:
calcd for $C_{41}H_{45}N_9O_{11}$ = 839.3 (monoisotopic), exp = 839.2.


Example 4 Activated Linkers

Activated linkers of the general formula



have been evaluated for their stability during chain assembly and their lability in the final cyclisation reaction. For the $n=0$ linker we have synthesised a series of constrained cyclic peptides, as illustrated in Table 5 below.

A general outline of the procedure used is shown in Scheme 9. The hydroxybenzoic acid (1) was acylated with Boc-Gly-OH. The resulting ester link was found to be stable to TFA treatment, as confirmed by treating compound (2) with TFA and subsequent 1H NMR analysis of the products (3).



Scheme 9

5

'Cyclisation by cleavage' experiments

Compound (2) was attached to amino-methylated resin (polystyrene) (substitution value (sv) = 0.21 mmol/g) using HBTU in DMF (Scheme 9). Peptide assembly was

10 monitored by quantitative ninhydrin tests, and indicated successful assembly of the linear sequence. This was confirmed by the increase in resin weight. The deprotection of the side chain protecting group was

15 achieved by treatment with HF/anisole (9/1) at -5°C for 1 hour. After HF evaporation, the resin was washed with ether.

Cyclisation and accompanying cleavage was achieved by treatment with 10 equivalents DIEA in DMF for 3 days. The reaction mixture was worked up by filtration

20 and the filtrate diluted with water and lyophilised. The

crude lyophilised product was redissolved in acetonitrile/water (1/1) and further analysed by analytical and preparative HPLC.

The HPLC profile of the crude product is shown in Figure 1. The major component is the target peptide, as is evidenced by HPLC comparison and a coelution experiment with solution phase synthesised material. This result illustrates the potential power of this strategy in synthesising constrained cyclic peptides, particularly when considering the surprising purity of the crude material. The yields of cyclic material are given in Table 5.

Table 5

Yields of Cyclic Peptide Using Activated Linker

15

<u>Linear tetrapeptide</u>	<u>Yield of Cyclisation</u>
cyclo-[DG-Act-RG]	11%
cyclo-[DG-Amb-RG]	7%; 3% dimer
cyclo-[D-Amb-GRG]	5% monomer; 5% dimer

20

Experimental to Example 4

This section describes the experimental details for the synthesis of the activated linker and model peptides.

25 Synthesis of Model Compounds Using Activated Linkers Cyclo [DGActRG] (Table 5)

Linker Resin

The aminomethylated resin (2.38 gr, 0.5 mmole) was first washed with 10% DIEA in DMF (5 min) and then washed with DMF (3 x 5 ml). Hydroxybenzoic acid (276 mg, 2 mmole) was dissolved in 4 ml 0.5M HBTU in DMF and DIEA (400 µL, 2.3 mmol) added. The activated solution was then added to the neutralised resin. After 10 min the resin was drained and washed with DMF (3 x 5 mL). A solution of aqueous sodium hydroxide (1M, 2 mL) in DMF (4 mL) was added to the resin and mixed for 10 minutes. The sodium

hydroxide treatment was repeated, and the resin washed with DMF/water (1/1) (3 x 5 mL) and then with DMF (3 x 5 mL).

Assembly of the Peptide

5 Boc-glycine was first coupled to the linker as follows. BocGlycine (350 mg, 2 mmole) was dissolved in 2 mL DCM and DIC (156 μ L, 1 mmole) added. After 15 min the solution was diluted with 2 mL DMF, and added to the resin with DIEA (400 μ L, 2.3 mmole). After 30 min, the resin was
10 drained and washed with DMF (3 x 5 mL). The Boc group was then removed using neat TFA (2 x 1 min). The next residues were coupled using the following *in situ* neutralisation protocol: 2 mmole of the Boc-protected amino acid was dissolved in 4 mL of an 0.5M HBTU solution in DMF, and
15 activated through addition of DIEA (460 μ L, 2.6 mmole). The activated solution was then added to the resin and mixed for 10 minutes. The resin was drained and washed with DMF. Neat TFA (2 x 1 min) was used again for deprotection of the *N*-terminus. The following residues
20 were coupled in series: Boc-Arg(Mts)OH, Boc-Gly-Cat-OH, Boc-Asp(OCHx)-OH.

Side-Chain Deprotection

 After assembly the *N*-terminal Boc-group was
25 removed with TFA as above, and the resin dried. The side chains were removed using HF treatment as follows: 1 gr of resin was mixed with 1 mL thioanisole and 9 mL of HF were added. The mixture was stirred at -5°C for 1 hour and the HF removed under reduced pressure. The resin was washed
30 with diethylether (3 x 20 mL) and dried.

Cyclisation

 The resin was stirred in DMF (10 mL) containing DIEA (100 μ L) for 12 hours. The resin was filtered off and
35 the DMF removed *in vacuo*. The residue was dissolved in a minimal amount acetonitrile/water (1/1) and loaded directly on a preparative reverse phase column for HPLC separation


of the product. Cyclo-[DGCatRG] (27 mg, 11% yield from the starting resin) was obtained.

The same protocols were followed to assemble, deprotect and cyclise the following peptides:

- 5 cyclo-[DGAmBRG]: 7.6% yield (3% dimer); cyclo-[DAmBRG] :
5% yield (5% dimer).

Example 5 Safety Catch Linkers

10 We have also evaluated the safety catch linkers
of the general class




Examples of safety catch linkers

15

Activation of this linker is achieved by removal of the benzyl group. The safety-catch linker ($n=2$) was synthesised as shown in Scheme 10.

20 We have found that better results are obtained
when n is 1 or 2, and therefore safety catch linkers of this type are preferred.

68



Scheme 8
Synthesis of safety catch linker

5


This safety-catch linker was attached to aminomethylated polystyrene using HBTU/DIPEA in DMF, then peptide assembly was accomplished using standard Boc protocols. Treatment of the resin with anhydrous HF in the presence of anisole as a scavenger at -5°C resulted in deprotection of the amino-acid side-chains, with concomitant removal of the benzyl group of the linker. The HF was evaporated and the resin was washed with diethyl ether to remove scavenger. Treatment of the resin with DIPEA in DMF for 48 h gave the crude cyclised product. An LC-MS profile of the crude cyclic material is shown in Figure 2. The major component is the desired cycle, and an appreciable amount of the cyclodimer is also present. Preparative-scale HPLC gave a mixture of the monomer and dimer, in an overall yield of approximately 50%.

20

Experimental to Example 5

This section describes the synthesis of one type of safety catch linker and model peptides.

5

Synthesis of Model Compounds using Safety Catch Linkers**Benzyl 4-Benzyloxy-3-hydroxybenzoate**

10

Benzyl bromide (1.50 cm³, 2.16 g, 12.6 mmol) was added to a stirred suspension of 3,4-dihydroxybenzoic acid (1.00 g, 6.49 mmol), potassium carbonate (1.97 g, 14.3 mmol) and a catalytic amount of tetrabutylammonium iodide in *N,N*-dimethylformamide (50 cm³). The suspension was stirred under nitrogen overnight then water (500 cm³) and 5% hydrochloric acid (50 cm³) were added, and the mixture was extracted with diethyl ether (3 x 100 cm³). The combined extracts were washed with water (3 x 100 cm³) and brine (100 cm³), then dried (Na₂SO₄) and evaporated to an orange oil. Flash column chromatography (eluent: 10-20% ethyl acetate in light petroleum) gave first benzyl 3,4-dibenzyloxybenzoate (168 mg, 6%), identical to that prepared above. Further elution then gave benzyl 4-benzyloxy-3-hydroxybenzoate (1.312 g, 60%) as a pale yellow oil. The position of the benzyloxy group was deduced from an n.o.e. observed between the proton at position 5 and the methylene protons of the benzyloxy group at position 4.

30

R_f 0.18 (20% EtOAc in light petroleum).

ν_{max} (thin film, NaCl) 3600-3200, 1715, 1615, 1590 cm⁻¹.

¹H NMR (300 Hz, CDCl₃) 5.17, 2H, s, CH₂; 5.34, 2H, s, CH₂; 5.73, 1H, bs, OH; 6.95, 1H, d(*J* 8.2), H₅; 7.32-7.46, 10H, Ar-H; 7.65, 1H, dd(*J* 2.0, 10.6), H₆; 7.66, 1H, s, H₂; OH not observed.

5


¹³C NMR (75 MHz, CDCl₃) 66.5, CH₂; 71.1, CH₂; 111.2, 115.9, - 122.9, 123.6, 127.8, 128.0, 128.1, 128.2, 128.5, 128.6, 128.8, 135.5, 136.2, 145.4, 149.6, 166.0, CO₂.

10 Mass spectrum: 335 (MH⁺).

Found: *M* 334.1205; C₂₁H₁₉O₄ requires *M*⁺ 334.1205.

4-Benzyloxy-3-hydroxybenzoic Acid

15



A solution of lithium hydroxide hydrate (300 mg, 7.15 mmol) in water (15 cm³) was added dropwise to a stirred solution of benzyl 4-benzyloxy-3-hydroxybenzoate (1.177 g, 3.52 mmol) in tetrahydrofuran (35 cm³). The resulting emulsion was stirred overnight, by which time a clear, pale yellow solution had formed. More lithium hydroxide hydrate (300 mg, 7.15 mmol), water (25 cm³) and tetrahydrofuran (25 cm³) were added, and stirring was continued for 24 h. The tetrahydrofuran was removed under reduced pressure. Water (100 cm³) was added to the residual mixture, which was washed with diethyl ether (2 x 50 cm³), acidified to pH 1 with 5% HCl and extracted with dichloromethane (3 x 100 cm³). The combined extracts were washed with brine (50 cm³), dried (NaSO₄) and evaporated to give 4-benzyloxy-3-hydroxybenzoic acid as a white solid (638 mg, 74%). The diethyl ether washings were extracted with 1 M potassium hydroxide (2 x 25 cm³). The

combined extracts were acidified to pH 1 with 5% HCl and extracted with dichloromethane ($3 \times 100 \text{ cm}^3$). The combined extracts were dried over MgSO_4 and evaporated to give a further 119 mg of product (total yield 757 mg, 88%), m.p.

5 163-165°C.

ν_{max} (KBr disc) 3555, 3200-2400, 1676, 1619, 1592 cm^{-1} .


^1H NMR (300 Hz, CDCl_3) 5.19, 2H, s, CH_2 ; 5.71, 1H, br s, OH; 6.98, 1H, d(J 9.0), H5; 7.38-7.45, 5H, Ar-H; 7.67, 1H, dd(J 8.9, 2.1), H6; 7.68, 1H, d(J 2.0), H2; CO_2H not observed.

^{13}C NMR (75 MHz, CDCl_3) 71.2, CH_2 ; 111.2, 116.3, 122.6, 123.5, 127.9, 128.7, 128.9, 135.4, 145.5, 150.2, 170.6, CO_2 .


Mass spectrum: 245 (MH^+).

20 Found: M 244.0740; $\text{C}_{14}\text{H}_{12}\text{O}_4$ requires M^+ 244.0736.

Allylation of 3,4-Dihydroxybenzoic acid: Preparation of Propen-2-yl 3,4-Bis(propen-2-yloxy)benzoate, Propen-2-yl 3-hydroxy-4-(propen-2-yloxy)benzoate and Propen-2-yl 3,4-dihydroxybenzoate



72



Allyl bromide (1.18 cm³, 1.65 g, 13.6 mmol) was added to a stirred suspension of 3,4-dihydroxybenzoic acid (1.00 g, 6.49 mmol) and potassium carbonate (1.97 g, 14.3 mmol) in dry *N,N*-dimethylformamide (50 cm³). After stirring overnight under an atmosphere of nitrogen, the mixture was poured into water (500 cm³), acidified with 5% hydrochloric acid and extracted with ethyl acetate (3 x 100 cm³). The combined extracts were washed with water (3 x 100 cm³) and brine (50 cm³), then dried over MgSO₄ and evaporated to a brown oil which was purified by flash column chromatography (eluent: 10-50% ethyl acetate in light petroleum). The first compound to elute was propen-2-yl 3,4-bis(propen-2-yloxy)benzoate as a pale yellow oil (460 mg, 26%).

R_f 0.43 (20% EtOAc in light petroleum).

ν_{\max} (thin film, NaCl) 1718, 1648, 1600, 1270 cm⁻¹.

¹H NMR (300 Hz, CDCl₃) 4.64, 2H, dt(*J* 1.6, 5.2), OCH₂; 4.66, 2H, dt(*J* 1.7, 5.1), OCH₂; 4.79, 2H, dt(*J* 1.5, 5.7), OCH₂; 5.24-5.47, 6H, m, 3x =CH₂; 5.97-6.15, 3H, m, 3x =CH; 6.88, 1H, d(*J* 8.5), H5; 7.58, 1H, d(*J* 2.0), H2; 7.67, 1H, dd(*J* 2.0, 8.4), H6.

¹³C NMR (75 MHz, CDCl₃) 65.3, 69.6 and 69.8, 3x CH₂O; 112.3 and 114.6, C2 and C5; 117.9, 117.9 and 118.0, 3x =CH₂; 122.7, C1; 123.7, C6; 132.4, 132.6 and 132.9, 3x CH=CH₂; 147.9, C3; 152.5, C4; 165.9, C=O.

Mass spectrum: 275 (MH⁺), 217 (MH-C₃H₅O)

Found: M 274.1204; $C_{15}H_{18}O_4$ requires M^+ 274.1205.

Next to elute was propen-2-yl 3-hydroxy-4-(propen-2-yloxy)benzoate as a pale pink oil (782 mg, 51%).

R_f 0.26 (20% EtOAc in light petroleum).

ν_{max} (thin film, NaCl) 3422 br, 1718, 1616, 1590, 1508 cm^{-1} .

10

1H NMR (300 Hz, $CDCl_3$) 4.67, 2H, dt (J 5.5, 1.4), OCH_2 ; 4.79, 2H, dt (J 5.5, 1.5), OCH_2 ; 5.25-5.45, 4H, m, $2x=CH_2$; 5.70, 1H, s, OH; 5.96-6.12, 2H, m, $2xCH=CH_2$; 6.87, 1H, d (J 8.7), H5; 7.62, 1H, dd (J 7.7, 2.2), H6; 7.63, 1H, br s, H2.

15

^{13}C NMR (75 MHz, $CDCl_3$) 65.4, OCH_2 ; 69.8, OCH_2 ; 111.1 and 115.8, C2 and C5; 118.0 and 119.0, $2x=CH_2$; 122.7, C6; 123.5, C1; 132.1 and 132.4, $2x=CH$; 145.4, C3; 149.4, C4; 165.9, C=O.

20

Mass spectrum: 235 (MH^+), 177 ($MH-C_3H_5O$), 149 ($MH-C_4H_5O_2$).

Found: M 234.0892; $C_{13}H_{14}O_4$ requires M^+ 234.0892.

25

Last to elute was propen-2-yl 3,4-dihydroxybenzoate as a pale yellow semi-solid (80.2 mg, 6%).

R_f 0.30 (50% EtOAc in light petroleum).

30 ν_{max} (KBr disc) 3468br, 3344br, 1693, 1613, 1445, 1300 cm^{-1} .

1H NMR (300 Hz, $CDCl_3$) 4.78, 2H, d (J 5.4), OCH_2 ; 5.27, 1H, br d (J 10.5), $=CHH$; 5.39, 1H, br d (J 18.6), $=CHH$; 5.94-6.07, 1H, m, $CH=CH_2$; 6.90, 1H, d (J 7.8), H5; 7.56, 1H, d (J 7.8), H6; 7.64, 1H, br s, H2; OHs not observed.

35


¹³C NMR (75 MHz, CDCl₃) 65.7, OCH₂; 114.8 and 116.3, C2 and C5; 118.3, =CH₂; 122.1, C1; 123.7, C6; 132.1, =CH; 143.3, C3; 149.2, C4; 166.9, C=O.

5 Mass spectrum: 195 (MH⁺).

Found: M 194.0578; C₁₀H₁₀O₄ requires M⁺ 194.0579.

Propen-2-yl 3-Benzyloxy-4-(propen-2-yloxy)benzoate

10



Benzyl bromide (0.440 cm³, 634 mg, 3.70 mmol) was added to a stirred mixture of propen-2-yl 3-hydroxy-4-(propen-2-yloxy)benzoate (782 mg, 3.34 mmol) and potassium carbonate (553 mg, 4.00 mmol) in *N,N*-dimethylformamide (30 cm³). The mixture was stirred under nitrogen overnight, then poured into water (300 cm³) and extracted with ethyl acetate (3 x 100 cm³). The combined extracts were washed with water (3 x 50 cm³) and brine (50 cm³), then dried over MgSO₄ and evaporated to a colourless oil. This was dissolved in dichloromethane and filtered through a plug of silica. Evaporation of the filtrate gave propen-2-yl 3-benzyloxy-4-(propen-2-yloxy)benzoate as a colourless oil (1.096 mg, 100%).

R_f 0.42 (20% EtOAc in light petroleum).

*v*_{max} (thin film, NaCl) 1714, 1600, 1514, 1428 cm⁻¹.

30

¹H NMR (300 Hz, CDCl₃) 4.67, 2H, dt(*J* 5.2, 1.6), =CH-CH₂; 4.79, 2H, dt(*J* 5.6, 1.5), =CH-CH₂; 5.19, 2H, s, PhCH₂; 5.29, 2H, ddt(*J* 10.2, 2.8, 1.5), =CH₂; 5.41, 2H, ddt(*J*

17.2, 3.1, 1.6), =CH₂; 5.96-6.15, 2H, m, 2x =CH; 6.91, 1H, d(J 8.5), H5; 7.30-7.49, 5H, PhCH₂; 7.66, 1H, d(J 2.0), H2; 7.69, 1H, dd(J 8.4, 2.0), H6.


5 ¹³C NMR (75 MHz, CDCl₃) 66.3, 69.6 and 71.0, 3x CH₂O; 112.5 and 115.2, 2x =CH; 117.9, 2x =CH₂; 122.7, C1; 127.3, 127.9, 128.5, 132.4 and 132.6, 5x CH; 136.7; 148.0 and 152.7, C3 and C4; 165.9, C=O.

10 Mass spectrum: 325 (MH⁺).

Found: M 324.1361; C₂₀H₂₀O₄ requires M⁺ 324.1362.

3-Benzyloxy-4-Hydroxybenzoic Acid

15



A mixture of propen-2-yl 3-benzyloxy-4-(propen-2-yloxy)benzoate (1.0356 g, 3.19 mmol), tris(triphenylphosphine)rhodium chloride¹ (204 mg, 0.22 mmol) and 1,4-diazabicyclo[2.2.2]octane (74 mg, 0.66 mmol) in ethanol (18 cm³) and water (2 cm³) was heated under reflux under an atmosphere of nitrogen for 16 h. The cooled mixture was poured into 1 M hydrochloric acid (100 cm³), stirred for 25 60 min, then extracted with dichloromethane (3 x 100 cm³). The combined extracts were dried over MgSO₄ and evaporated to an orange solid which was purified by flash column chromatography (eluent: 1:1 EtOAc:light petroleum) to give 3-benzyloxy-4-hydroxybenzoic acid as an orange solid 30 (650 mg, 83%), m.p. 167.2-171.3°C

R_f 0.25 (50% EtOAc in light petroleum).

ν_{\max} (KBr disc) 3528, 3200-2600, 1700, 1673, 1611 cm^{-1} .

¹H NMR (300 Hz, CDCl_3) 5.18, 2H, s, CH_2 ; 6.13, 1H, br s, OH; 7.00, 1H, d(J 8.3), H5; 7.37-7.50, 5H, m, Bn-H; 7.71, 1H, d(J 1.9), H2; 7.75, 1H, dd(J 1.9, 8.3), H6; CO_2H not observed.


¹³C NMR (75 MHz, CDCl_3) 71.4, CH_2 ; 113.5, 114.4, 121.2, 125.5, 128.1, 128.7, 128.8, 135.6, C1; 145.4 and 151.0, C3 and C4; 171.0, C=O

Mass spectrum: 245 (MH^+)

Found: M 244.0731; $\text{C}_{14}\text{H}_{12}\text{O}_4$ requires M^+ 244.0736.

1. Corey, E.J. and Suggs, J.W., J. Org. Chem., 1973 38 3224.

Benzyl 3-(*tert*-Butyldimethylsilyloxy)-4-benzyloxybenzoate



20

A solution of *tert*-butyldimethylsilyl chloride (579 mg, 3.84 mmol) in dichloromethane (10 cm^3) was added to a stirred solution of benzyl 4-benzyloxy-3-hydroxybenzoate (642.3 mg, 1.92 mmol) and imidazole (327 mg, 4.80 mmol) in dichloromethane (15 cm^3). A thick precipitate formed immediately. After 1 h the mixture was poured into water (50 cm^3). The layers were shaken and separated and then the aqueous phase was further extracted with dichloromethane (2 x 50 cm^3). The combined extracts were washed with brine (50 cm^3) then dried (Na_2SO_4) and evaporated to a pale yellow oil. This was taken up in 20% ethyl acetate in petroleum ether and filtered through a plug of silica. Evaporation of the filtrate gave the title

compound as a pale yellow oil (936 mg) which was used immediately for the next step.

R_f 0.49 (20% EtOAc in hexane).

5


ν_{\max} (NaCl film) 1718, 1599, 1509, 1427, 1290, 1213, 837 cm^{-1} .

^1H NMR (300 Hz, CDCl_3) 0.11, 6H, s, SiMe_2 ; 0.96, 9H, s, CMe_3 ; 5.10, 2H, s, CH; 5.33, 2H, s, CH_2 ; 6.92, 1H, d(J 8.7), H5; 7.31-7.45, 10H, 10 x Bn-H; 7.59, 1H, d(J 1.5), H2; 7.67, 1H, dd(J 2.2, 8.9), H6.

^{13}C NMR (75 MHz, CDCl_3) -4.6, SiMe_2 ; 18.4, CMe_3 ; 25.6, CMe_3 ; 66.4 and 70.7, $2 \times \text{CH}_2$; 112.5, 122.2, 124.3, 127.8, 127.9, 128.1, 128.2, 128.3, 128.5, 136.2, 136.4, 144.9, 154.5, Ar-C; 166.1, C=O.

3-(*tert*-Butyldimethylsilyloxy)-4-hydroxybenzoic Acid

20



A solution of the crude silyl ether (936 mg, 2.09 mmol) in ethanol (50 cm^3) containing 10% palladium-on-carbon (80 mg) was shaken under an atmosphere of hydrogen at 25 p.s.i. for 48 h. The mixture was filtered through celite and evaporated, then the residue was taken up in ethyl acetate and filtered through a plug of silica to give the title compound as a pale green oil (424 mg, 76%).


30

ν_{\max} (NaCl film) 3516, 3400-2600, 1682, 1597, 1298 cm^{-1} .

^1H NMR (300 Hz, CDCl_3) 0.33, 6H, s, SiMe_2 ; 1.04, 9H, s, CMe_3 ; 6.05, 1H, brs, OH; 6.99, 1H, d(J 8.4), H5; 7.60, 1H, d(J 2.1), H2; 7.73, 1H, dd(J 1.9, 8.5), H6.

^{13}C NMR (75 MHz, CDCl_3) -4.4, SiMe_2 ; 18.2, CMe_3 ; 25.6, CMe_3 ; 114.6, 119.3, 121.3, 125.5, 142.1, 152.5, 6xArC; 171.9, C=O.

Benzyl 4-benzyloxy-3-(tert-Butyldiphenylsilyloxy)benzoate



15

A solution of *tert*-butyldiphenylsilyl chloride (850 mg, 3.09 mmol) in dichloromethane (10 cm^3 + 5 cm^3 rinse) was added to a stirred solution of benzyl 4-benzyloxy-3-hydroxybenzoate (827 mg, 2.47 mmol) and imidazole (421 mg, 6.18 mmol) in dichloromethane (15 cm^3). After a few minutes a precipitate formed. The mixture was stirred overnight under an atmosphere of nitrogen, then was poured into water (50 cm^3). The layers were shaken and separated, then the aqueous phase was further extracted with dichloromethane (2 x 50 cm^3). The combined extracts were washed with brine (50 cm^3) and evaporated to a pale yellow oil. This was filtered through a short silica column and eluted with 20% ethyl acetate in petroleum ether. Evaporation of the filtrate gave benzyl 3-(*tert*-butyldiphenylsilyloxy)-4-benzyloxybenzoate (1.646 g) as a

25

30

very pale yellow oil, containing some *tert*-butyldiphenylsilanol, which was used directly for the next step.

R_f 0.37 (20% EtOAc in hexane).

5


ν_{\max} (NaCl, thin film) 1715, 1599, 1510, 1427, 1291 cm^{-1} .

^1H NMR (300 Hz, CDCl_3) 1.13, 9H, s, CMe_3 ; 4.93, 2H, s, CH_2O ; 5.25, 2H, s, CH_2O ; 6.84, 1H, d(J 8.9), H5; 7.21-7.43, 16H, m, 16xAr-H; 7.55, 1H, d(J 2.1), H2; 7.63, 1H, dd(J 2.1, 8.4), H6; 7.70-7.79, 4H, m, 4xAr-H.

^{13}C NMR (75 MHz, CDCl_3) 19.7, CMe_3 ; 26.6, CMe_3 ; 66.2 and 70.3, 2x CH_2O ; 112.4, 121.4, 122.6, 124.1, 127.4, 127.5, 127.7, 127.8, 127.9, 128.3, 128.4, 129.7, 133.1, 134.8, 135.3, 136.2, 144.7 and 153.8, 18xAr-C; 165.9, C=O.

Synthesis of Model Compounds Using Safety Catch Linker.

20 **Methyl 3-(3,4-Dihydroxyphenyl)Propionate**



A solution of 3-(3,4-dihydroxyphenyl)propionic acid (1.00 g, 5.49 mmol) and concentrated H_2SO_4 (10 drops) in methanol (25 cm^3) was heated under reflux overnight. The solvent was evaporated and the residue was shaken with water (50 cm^3) and extracted into CHCl_3 (3 x 50 cm^3). The combined extracts were dried (Na_2SO_4) and evaporated to gave the methyl ester a pale yellow oil which crystallised

30

on standing (1.12g, 100%), m.p. 71.9-74.1°C (lit.¹ m.p. 74-76°C).

n_{\max} (KBr disc) 3485, 3311, 1712 cm^{-1} .

5

¹H NMR (300 Hz, CDCl_3) 2.61, 2H, t(J 7.5), CH_2CO_2 ; 2.83, 2H, t(J 7.6), ArCH_2 ; 3.69, 3H, s, OMe; 5.40, 2H, br s, 2xOH; 6.61, 1H, dd(J 2.1, 8.1), H6; 6.71, 1H, d(J 2.0), H2; 6.77, 1H, d(J 8.1), H5.


10

¹³C NMR (75 MHz, CDCl_3) 30.2 and 35.9, 2x CH_2 ; 51.9, OMe; 115.4, C2 and C6; 120.5, C5; 133.2, C1; 142.1 and 143.6, C3 and C4; 174.3, C=O.

15 Mass spectrum: (MH^+).

Found: M 196.0739; $\text{C}_{10}\text{H}_{12}\text{O}_4$ requires M^+ 196.0736.
Freudenberg and Heel, (1953)

20 **Methyl 3-(3-Benzyloxy-4-hydroxyphenyl)Propionate and Methyl 3-(4-Benzyloxy-3-hydroxyphenyl)Propionate**



25

Benzyl bromide (0.606 cm^3 , 872 mg, 5.20 mmol) was added to a stirred suspension of methyl 3-(3,4-dihydroxyphenyl)propionate (1.000 g, 5.10 mmol), K_2CO_3 (845 mg, 6.12 mmol) and a catalytic amount of tetrabutylammonium iodide in DMF (25 cm^3). The suspension was stirred overnight under an atmosphere of nitrogen. Water (500 cm^3) and 5% HCl (50 cm^3) were added, and the mixture was extracted with diethyl ether (3 x 100 cm^3). The combined extracts were washed with water (3 x 100 cm^3) and brine

30

(100 cm³), then dried (Na₂SO₄) and evaporated to a brown oil which was purified by flash chromatography (5-20% EtOAc in petrol) to give a 1:1 mixture of the monobenzyl ethers as a colourless oil (1.150 g, 79%)

5

n_{\max} (NaCl thin film) 3446, 1732, 1592, 1514 cm⁻¹.

¹H NMR (300 Hz, CDCl₃) 2.60, 4H, t(J 7.4), 2xCH₂CO₂; 2.87, 2H, t(J 7.8), CH₂CH₂CO₂; 2.89, 2H, t(J 7.7), CH₂CH₂CO₂; 10 3.67, 3H, s, OMe; 3.68, 3H, s, OMe; 5.08, 2H, PhCH₂; 5.09, 2H, PhCH₂; 6.67, 1H, dd(J 8.2, 2.1), H₆; 6.73, 1H, dd(J 8.0, 1.6), H₆; 6.81, 2H, br s, H_{2,2}; 6.82, 1H, d(J 8.0), H₅; 6.88, 1H, d(J 8.2), H₅; 7.30-7.50, 10H, Ar-H.

¹³C NMR (75 MHz, CDCl₃) 30.3, 30.6, 35.7 and 36.0, 2xCH₂CH₂; 15 51.5, 2xOMe; 71.0 and 71.1, PhCH₂; 112.2, 112.4, 114.6 and 114.7, C2 and C6; 119.6 and 121.2, C5; 127.2, 127.3, 127.7, 127.8, 128.2, 128.3, 128.4 and 128.6, Bn-C; 132.4 and 134.2, C1; 144.2, 145.6 and 145.8, C3 and C4; 173.3, CO₂.

20

3-(3-Benzyloxy-4-hydroxyphenyl)Propionic Acid and 3-(4-Benzyloxy-3-hydroxyphenyl)Propionic Acid

A solution of lithium hydroxide monohydrate (5.25 g, 125 mmol) in water (150 cm³) was added to a 25 stirred solution of the mixture of methyl esters (11.95 g, 41.7 mmol) in THF (150 cm³). The resulting mixture was stirred under an atmosphere of nitrogen. Next morning a clear, pale yellow solution had formed. The THF was evaporated and the residue was diluted with water (150 cm³) and acidified to pH 3 with 5% HCl. The mixture was 30 extracted with CHCl₃ (3 x 350 cm³), and the combined extracts were dried (Na₂SO₄) and evaporated to a brown oil which solidified on standing. This was taken up in EtOAc and passed through a short silica column. Evaporation of 35 the eluent gave the product as a tan solid (11.12 g, 98%).

n_{max} (KBr disc) 3533, 3471, 3300-2600, 1718, 1699,
1515 cm^{-1} .


^1H NMR (300 Hz, CDCl_3) 2.66, 4H, t(J 7.6), CH_2CO_2 ; 2.90, 2H,
5 t(J 7.6), $\text{CH}_2\text{CH}_2\text{CO}_2$; 2.91, 2H, t(J 7.7), $\text{CH}_2\text{CH}_2\text{CO}_2$; 5.09,
2H, s, PhCH_2 ; 5.10, 2H, s, PhCH_2 ; 6.69, 1H, dd(J 8.3, 2.1),
H6; 6.75, 1H, dd(J 8.1, 2.0), H6; 6.83, 1H, d(J 1.9), H2;
6.84, 1H, d(J 2.0), H2; 6.87, 1H, d(J 8.4), H5; 6.90, 1H,
d(J 8.2), H5; 7.30-7.50, 10H, m, Ar-H; CO_2H not observed.

10

^{13}C NMR (75 MHz, CDCl_3) 29.9, 30.2, 35.7 and 35.9, $2\times\text{CH}_2\text{CH}_2$;
71.1 and 71.2, PhCH_2 ; 112.3, 112.4, 114.6 and 114.7, C2 and
C6; 119.6 and 121.2, C5; 127.2, 127.3, 127.7, 127.8, 128.3,
128.4 and 128.7, Bn-C; 132.0 and 136.2, C1; 144.3, 145.6
15 and 145.8, C3 and C4; 179.2, CO_2 .

**3-(3-Benzyloxy-4-(*N*-tert-Butoxycarbonyl)glycyloxy)Phenyl-
propionic Acid and 3-(4-Benzyloxy-3-(*N*-tert-
Butoxycarbonyl)glycyloxy)Phenyl propionic Acid**

20




Triethylamine (1.40 cm^3 , 1.01 g, 10.0 mmol) and
ethyl chloroformate (0.960 cm^3 , 1.085 g, 10.0 mmol) were
25 added to a stirred, chilled (-20°C) solution of Boc-Gly-OH
(1.75 g, 10.0 mmol) in dichloromethane (20 cm^3). The
solution was stirred for 20 min at $-10 - -15^\circ\text{C}$, during
which time a precipitate formed. A solution of
regioisomeric mixture of benzyloxyacids (2.86 g, 10.0 mmol)
30 and triethylamine (1.40 cm^3 , 1.01 g, 10.0 mmol) in
dichloromethane (20 cm^3 + 5 cm^3 rinse) was then added
dropwise. The resulting solution was stirred at $-5 - 0^\circ\text{C}$
for 2 h, then was washed with 10% citric acid (2 x 10 cm^3)

and brine (10 cm³), then dried (Na₂SO₄) and evaporated to a syrup. This was dissolved in a little 1:1 ethyl acetate/petroleum ether and passed through a short silica column. Evaporation of the eluent gave the mixture of
5 title carboxylic acids as a colorless syrup (3.986 g, 93%).

¹H NMR (300 Hz, CDCl₃) 1.47, 9H, s, CMe₃; 2.65, 2H, br t(J 6.6), CH₂CO₂H; 2.85-2.95, 2H, m, CH₂CH₂CO₂H; 4.15-4.17, 2H, m, NHCH₂; 5.07, 2H, s, PhCH₂O; 5.08-5.15, 1H, m, NH;
10 6.66-7.04 and 7.29-7.46, 8H, Ar-H; CO₂H not observed.

¹³C NMR (75 MHz, CDCl₃) 28.3, CMe₃; 29.6, 30.4, 35.3 and 35.6, 2xCH₂CH₂; 42.3, NHCH₂; 70.7 and 71.3, 2xPhCH₂O; 80.1, CMe₃; 155.6, NCO₂; 178.0 and 178.4, 2xCO₂.
15

Solid-Phase Synthesis of cyclo-[D-G-Amb-R-G]



Aminomethyl resin (Peptide Institute, 0.83 mmol/gram, 602 mg, 0.50 mmol) was shaken with
20 10% DIPEA in DMF for 30, then drained and washed well with DMF.

The benzyloxy linker (429 mg, 1.0 mmol, 2.0 equiv.) was coupled using standard HBTU/DIPEA protocols overnight. The remaining residues were coupled using
25 standard HBTU/DIPEA protocols for ten minutes each. The final yield of the dried resin was 906 mg. Of this, 725 mg (ca. 0.4 mmol) was cleaved with anhydrous HF using anisole as the scavenger. The resin was washed well with diethyl ether, dried at suction, then gently stirred in 5.0 cm³ DMF
30 containing 0.5 cm³ DIPEA for 48 h. The resin was filtered off and washed well with DMF. Evaporation of the filtrate, followed by preparative HPLC gave cyclo-[D-G-Amb-R-G] as a fluffy white solid (103 mg, 49%). Analysis of the product

by LC-MS indicated the presence of the cyclodimer, cyclo-[D-G-Amb-R-G-D-G-Amb-R-G]. The ratio of monomer to dimer was approximately 3:2.

5 Example 6 Backbone substitution and activated or safety
 catch linker

This example illustrates that the use of the safety-catch linker with backbone substitution is a useful combination for the synthesis of cyclic peptides.

10 The sequence Ala-Phe-Leu-Pro-Ala does not cyclize under solution conditions (Schmidt and Lagner, 1997) using BOP/DIEA or under on-resin conditions using the safety-catch linker. However, when the backbone substitution method is applied in combination with the safety-catch
15 linker a substantial amount of cyclic product is obtained. For example, the synthesis and cyclisation of Ala-(Me)Phe-Leu-Pro-Ala yields cyclic product as characterised by ES-MS. Although in this instance the backbone substitution was a methyl group, one skilled in the art would realise
20 that numerous other substituents may also be used, including reversible substituents such as HMB and HnB.

Experimental to Example 6

The assembly of the peptide was carried out using standard
25 *in situ* neutralization Boc-SPPS protocols on aminomethylated polystyrene resin (sv=0.26meq/g) derivatised with the safety-catch linker as previously described (see Example 5). After coupling of Boc-(Me)Phe-OH and removal of the Boc group, the peptide was acylated
30 using a solution of the symmetric anhydride of Boc-Ala, prepared from Boc-Ala (10eq) and DIC (5eq) in DCM. The resin was then treated with TFMSA/TFA/p-cresol (1:10:1) for 2h to remove the benzyl group for linker activation. The resin was then washed with TFA (3 x 10mL), DCM (3 x 10mL)
35 and DMF (3 x 10mL). The resin was then treated with 2% DIEA in DMF overnight. The solvent was removed on the Genevac and the residue resuspended in acetonitrile/water and


analyzed by ES-MS and reversed phase HPLC. The ES-MS spectrum displayed a major peak at the expected m/z value for the cyclo-[Ala-(Me)Phe-Leu-Pro-Ala] calculated for $C_{27}H_{39}N_5O_5 = 513.3$ (monoisotopic), $exp = 513.3$.

5

Example 7 Ring contraction and activated or safety catch linker

In Example 2, a ring contraction auxiliary (HnB) was used to synthesise a difficult cyclic pentapeptide. In this example, we examine the combination of these auxiliaries with activated or safety catch linkers.

The array of compounds listed below is synthesised using activated or safety catch linkers and ring contraction auxiliaries. The effects of this combination on the yield and purity of the product are evaluated.




$HX \sim$ = ring contraction auxiliary;
X= O,S; L=activated or
safety catch linker

Example 8 Ring contraction, backbone substitution and activated or safety catch linker

20

The combination of all three approaches provides the preorganising advantages of backbone substitution and ring contraction with the advantages of activated and safety catch linker cyclisation and concomitant cleavage.

25



Scheme 11

- 5 In this example we show that the combination of ring contraction and backbone substitution can also be applied in an on-resin cyclisation strategy. The selected sequence, [Hnb]Gly-[Hnb]Tyr-Arg-Phe, cyclises readily in solution, as illustrated in Example 3. We have applied our
- 10 safety-catch linker (Example 5) to generate the target cyclic peptide directly from resin.

Experimental to Example 8

- 15 The assembly of the peptide was carried out on Boc-Phe-Linker-resin, which was synthesised in the standard manner (see example 6; the resin was aminomethylated resin, sv=0.26meq/gr). The peptide was then assembled using *in situ* neutralisation protocols and Boc-SPPS as described
- 20 previously. The Hnb group was introduced using the standard reductive amination approach. Special care was


taken to minimise the time of exposure to NaBH_4 (1 eq. of NaBH_4 for 1 min), as this can cause premature cleavage of the peptide from the resin. After introduction of the first Hnb group, Boc-Gly was attached via its HBTU activated ester (overnight). The resin was further treated with 1% piperidine (5 min) to remove the O-acylation on the phenol⁻ (Hnb). Following introduction of the second Hnb group as described above, the resin was treated with HF/p-cresol (9/1; 1h at 0°C) to remove the side-chain protection groups and the benzyl group for linker activation. The resin was then washed with ether (3 x 10 mL), DMF (3 x 10 mL), DCM/MeOH (10 mL) and dried under high vacuum for 2h. The resin was then treated with 1% DIEA in DMF overnight. After removal of the solvent, the residue was resuspended in acetonitrile/water and analysed by ES-MS and reversed phase HPLC. The ES-MS spectrum displayed a major peak at the expected m/z value for the cyclo-[[Hnb]Gly-[Hnb]Tyr-Arg-Phe] (calculated for $\text{C}_{40}\text{H}_{43}\text{N}_9\text{O}_{11} = 825.3$ (monoisotopic), exp M = 825.4 gr/mol).

20


Backbone Linkers

A common approach to synthesising cyclic peptides is attachment of a C-terminal protected amino acid to the resin through its side chain:

25



Method A



Method B


30 . Methodologies for peptide cyclisation on resin.

Method A - Side chain attachment


Method B - Backbone attachment

The procedure is widely applied, as it has the advantage of performing the cyclisation while the peptide is still attached to the resin, thus providing a pseudo-dilution environment. The cyclised peptide is then deprotected and cleaved to yield unprotected cyclic peptide. However, from a library perspective this strategy is inadequate because it is restricted to the attachment of specific amino acids to the resin. In an attempt to overcome these problems we have developed two backbone linkers which anchor the peptide to the resin via the first *N*-amide at the C-terminus.

The main advantage of the backbone linking approach is that it allows flexibility in selecting the linear precursor, *ie.* the position of cyclisation. This is important, as yields of cyclisation are known to be dependent on the selection of the linear precursor. We have designed and developed two backbone linkers. Linker (7) permits Boc chemistry, *ie.* stable to neat TFA but is cleaved with HF, while linker (8) permits Fmoc chemistry, *ie.* is cleaved by TFA (95%):



(7)




(8)

Backbone linkers investigated


Example 9 Linker (7)

As an example we studied the synthesis of stylostatin. This cyclic heptapeptide was originally


isolated from *Stylotella aurantium*, and found to be highly cytotoxic.



Stylostatin



a




b

Linker-dipeptide units

5 The structure of stylostatin and the two linkers
a and b that are used for the synthesis of stylostatin

10 The two linker-dipeptide units, depicted above,
were prepared in solution as outlined in Scheme 9, and
linked to aminomethylated resin; a and b refer to the
linking position on the stylostatin backbone on which the
attachment to resin is made.



Scheme 12

Reagents and Conditions:

- 5 i, BrCH₂CH₂CH₂CH₂CO₂Si(CH₃)₃, K₂CO₃, Acetone, Δ, 16 h;
- ii, H-Phe-Oallyl or H-Ile-Oallyl, MgSO₄, CH₂Cl₂, r.t., 3h;
- iii, NaBH₃CN, MeOH, r.t., 2 h;
- iv, (Boc-Pro)₂-O, DIEA, DMF, r.t., 16 h.; or
Boc-Ala-F, DIEA, THF, r.t., 30 min.;
- 10 v, TBAF, THF, r.t., 2 h.

The linear precursor sequences were then assembled on resin using *in situ* neutralisation protocols. Removal of the C-terminal allyl protection group was accomplished using Pd(Ph₃P)₄. The resin-bound linear peptide was further cyclised using BOP/DIEA activation. After deprotection and cleavage (HF), products were

separated, analysed and weighed. The reaction products consisted mainly of cyclic monomer and cyclic dimer. The results are shown in Table 6, in which the amino acid sequence is given in single-letter code.

5

Table 6

Yields of Cyclic Peptides Using Backbone Linker Approach

Resin-bound linear sequence	Backbone linking position	C-terminal	N-terminal	Yield	
				monocycle	dimer
PFNSLAI	a	Ile	Pro	25	<1
NSLAIPF	B	Phe	Asn	10	24



10 These results emphasise several interesting
points. First of all, the backbone linking strategy is a
feasible route towards generating cyclic peptides. The
yields of isolated material, based on the substitution
value of the starting resin, compare well with the overall
15 yields obtained from solution phase cyclisation.
Secondly, the cyclisation yields differ significantly for
the two precursors in terms of monomer versus dimer. This
illustrates the advantage of the backbone linking approach
over previous on-resin cyclisation approaches, ie. being
20 able to choose several precursors to the same cyclic
peptide. It is generally impossible to predict the optimal
precursor for cyclisation. This solid phase strategy
allows one to simultaneously assemble several precursors
and compare their cyclisation profiles in a fast and
25 efficient way.

Experimental to Example 10

This section describes the synthetic details for
the synthesis of a backbone linker and model peptides using
30 Boc chemistry.

Synthesis of backbone linker (Scheme 12) and model compounds using Boc Chemistry (Table 6)

4-[5-oxy-(trimethylsilylethylvalerate)]benzaldehyde




Exact Mass: 322.16

Mol. Wt.: 322.47

4-Hydroxybenzaldehyde (12.2 g, 0.10 mmol),
5-bromo (trimethylsilylethyl)valerate (13.82 g, 0.20 mol),
and K_2CO_3 (40.0 g, 0.29 mol) were refluxed in acetone
15 (250 mL) for 16 h. Solids were filtered, washed with
acetone and the volatiles were removed in vacuo. The
product was purified by column chromatography (Hexane :
EtOAc, 8:1) to yield a colourless oil (28.2 g, 87%) ^1H NMR
(CDCl_3): δ 9.87 (s, 1H, CHO), 7.82 (d, 2H, J = 7.0 Hz,
20 H_{arom}), 6.98 (d, 2H, J = 7.0 Hz, H_{arom}), 4.20 (t, 2H,
 J = 6.9 Hz, OCH_2), 4.05 (t, 2 H, J = 6.0 Hz, OCH_2),
2.42 (m, 2H, CH_2CO), 1.80 (m, 4H, CH_2CH_2), 0.96 (t, 2H,
 J = 6.9 Hz, CH_2Si), 0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$; ^{13}C NMR (CDCl_3) δ
190.80, 173.45, 164.026, 131.99, 131.99, 129.87, 114.72,
25 114.72, 67.82, 62.63, 34.00, 28.49, 21.55, 17.35, -1.49; MS
[$\text{M}+\text{H}$] $^+$ = 323.4 (expected 323.2).

N-[4-(5-oxy-(trimethylsilyl)ethylvalerate))benzyl]-L-Phenylalanine allyl ester



5

C₂₉N₄NO₅Si


Exact Mass: 511.28

Mol. Wt.: 511.73

- The aldehyde (16.2 g, 50.2 mmol), phenylalanine allyl ester (20.5, 100 mmol) and excess MgSO₄ (~40 g) were stirred in CH₂Cl₂ (75 mL) at r.t. for 16 h. Solids were filtered and volatiles were removed in vacuo to yield the crude imine as a yellow oil. MeOH (200 mL) and HOAc (3 mL) was added and the reaction mixture was cooled to 10°C.
- NaCNBH₃ (6.1 g, 100 mmol) was added portionwise to the stirred solution. The reaction mixture was allowed to warm to room temperature before being stirred for a further 2 h. Volatiles were removed in vacuo and the resulting residue diluted with H₂O (100 mL) and extracted with EtOAc (3 x 100 mL). The combined EtOAc extractions were washed with saturated brine (1 x 200 mL) and water (1 x 200 mL) before being dried over MgSO₄. Volatiles were removed in vacuo, and the resulting oil purified by flash chromatography (Hexane EtOAc, 1:1) to yield a clear colourless oil (20.2 g, 79%): ¹HNMR (CDCl₃) δ 7.28 (m, 5H, H_{arom}), 7.20 (d, 2H, J = 7.0 Hz, H_{arom}), 6.85 (d, 2H, J = 7.0 Hz, H_{arom}), 5.80 (m, 1H, CH=CH₂), 5.28 (dd, 1H, J = 12.1 Hz, 1.7 Hz, CH=CH₂), 5.23 (dd, 1H, J = 10.0 Hz, 1.7 Hz, CH=CH₂), 4.55 (d, 2H, J = 6.4 Hz, PheCH₂NH₂), 4.15 (t, 2H, J = 6.9 Hz, OCH₂), 3.92 (m, 2H, OCH₂), 3.80 (dd, 2H, J = 12.2 Hz, 1.2 Hz, CH₂-CH), 3.65 (dd, 2H, J = 11.7 Hz, 1.2 Hz, CH₂-CH), 3.58 (m, 1H, CHNH), 3.05 (m, 1H, CH₂Ph), 2.25

(m, 2H, CH₂CO), 1.80 (m, 4H, CH₂CH₂), 0.95 (t, 2H, J = 6.9 Hz, CH₂Si), 0.10 (s, 9H, Si(CH₃)₃); ¹³CNMR (CDCl₃) δ 173.56, 173.00, 158.32, 136.78, 131.96, 130.67, 129.57, 129.57, 129.27, 129.27, 128.39, 128.39, 126.76, 118.77, 114.36, 114.36, 67.33, 66.48, 62.51, 61.60, 51.13, 39.18, 34.08, 28.68, 21.62, 17.32, -1.51; MS [M+H]⁺ = 512.1 (expected 512.3).

Boc-L-Pro-[N-(4-(5-oxy-(trimethylsilyl)ethylvalerate))-benzyl]-L-Phenylalanine allyl ester



C₃₉H₅₆N₂O₈Si


Exact Mass: 708.38

Mol. Wt.: 708.96

Boc-Pro-OH (8.61 g, 40.0 mmol) was dissolved in EtOAc (30 mL), to which was added DCCI (4.12 g, 20.0 mmol). After activation for 10-15 min to form the symmetric anhydride, the mixture was filtered and the filtrate was added to a solution of the amine (6) (5.11 g, 10.0 mmol) and DIEA (2.67 mL, 15 mmol). The reaction was stirred at r.t. for 16 h. EtOAc (100 mL) was added and the reaction mixture was washed with 10% K₂CO₃ solution (2 x 250 mL), brine (1 x 250 mL) and H₂O (1 x 250 mL) before dried over MgSO₄. Volatiles were removed in vacuo, and the resulting oil purified by flash chromatography (Hexane : Et₂O, 5:1) to yield a clear colourless oil (3.55 g, 60%): ¹HNMR (CDCl₃) δ 7.20 (m, 7H, H_{arom}), 6.85 (d, 2H, J = 7.0 Hz, H_{arom}), 5.98 (m, 1H, CH=CH₂), 5.20 (m, 2H, CH=CH₂), 4.50 (m,

3H, CH₂CH and PheCH₂N), 4.20 and 4.13 (rotomers, dd, 1H, J = 7 Hz, 2 Hz, NCH), 4.15 (t, 2H, J = 6.9 Hz, OCH₂), 3.92 (m, 2H, OCH₂), 3.71 (m, 2H, CH₂-CH), 3.31 (m, 4H, CH₂Ph and CH₂N), 2.25 (m, 2H, CH₂CO), 2.05 (m, 4H, CH₂CH₂), 1.80 (m, 4H, CH₂CH₂), 1.48 (br s, 9H, C(CH₃)₃), 0.95 (t, 2H, J = 6.9 Hz, CH₂Si), 0.10 (s, 9H, Si(CH₃)₃); ¹³CNMR (CDCl₃) δ rotomers 173.54 and 173.00, 172.42, rotomers 170.08 and 169.47, rotomers 158.68 and 158.50, rotomers 154.31 and 153.98, rotomers 138.35 and 138.05, rotomers 132.45 and 131.96, 129.40, 129.40, 129.10, 128.91, 128.63, 128.63, 127.52, rotomers 126.75 and 126.62, rotomers 118.26 and 118.06, 114.32, 114.32, rotomers 79.96 and 79.19, 67.34, rotomers 65.96 and 65.80, 62.55, rotomers 60.68 and 60.58, rotomers 57.44 and 56.94, 51.37, rotomers 46.83 and 46.77, rotomers 35.11 and 34.97, 34.07, rotomers 30.84 and 29.78, 28.67, 28.46, rotomers 24.02 and 22.77, 21.68 17.32, -1.50; MS [M+H]⁺ = 709.6 (expected 709.4).

Boc-L-Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Phenylalanine allyl ester



Exact Mass: 608.31

Mol. Wt.: 608.72

25

The ester (2.0 g, 2.82 mmol) was stirred in a solution of THF (20 mL) at r.t. TBAF (3 mL, 1M) was added dropwise and saponification proceeded for 3 h. H₂O (100 mL) and HOAc (3 mL) was added to the reaction mixture. The acid was extracted into EtOAc (3 x 100 mL) and was

30

washed H₂O (1 x 250 mL) before being dried over MgSO₄. Volatiles were removed in vacuo, and the resulting oil purified by flash chromatography (Hexane : Et₂O, 5:1) to yield a clear colourless oil. The tertiary amide

5 (product) was purified by column chromatography (CH₂Cl₂: MeOH, 19:1) to yield a white solid (2.54 g, 90%); mp. 28-30°C : ¹HNMR (CDCl₃) δ 8.89 (br s, 1H, OH), 7.20 (m, 7H, H_{arom}), 6.75 (dd, 2H, J = 7.1 Hz, 1.9 Hz, H_{arom}), 5.88 (m, 1H, CH=CH₂), 5.25 (m, 2H, CH=CH₂), 4.50 (m, 3H, CH₂CH and PheCH₂N), 4.20 and 4.13 (rotomers, dd, 1H, J = 6.9 Hz, 1.9 Hz, NCH), 3.88 (m, 2H, CH₂O), 3.71 (m, 2H, CH₂-CH), 3.41 (m, 4H, CH₂N, CH₂Ph), 2.25 (m, 2H, CH₂CO), 2.05-1.85 (m, 8H, 2 x CH₂CH₂), 1.48 (br s, 9H, C(CH₃)₃; ¹³CNMR (CDCl₃) δ rotomers 179.09 and 177.04, 173.05, rotomers 170.08 and 15 169.48, rotomers 158.64 and 158.44, rotomers 154.28 and 153.96, rotomers 138.31 and 138.02, rotomers 132.43 and 131.94, 129.41, 129.41, 128.99, 128.69, 128.48, 128.48, 127.50, rotomers 126.78 and 126.65, rotomers 118.30 and 118.10, 114.37, 114.37 rotomers 80.17 and 79.38, 67.30, 20 rotomers 65.99 and 65.84, rotomers 60.72 and 60.54, rotomers 57.49 and 57.00, 51.40, rotomers 46.86, rotomers 35.09 and 34.95, 33.56, rotomers 30.83 and 29.78, rotomers 28.46 and 20.76, rotomers 24.00 and 22.78, 21.39; MS [M+H]⁺ = 609.3 (expected 609.3).



25

N-[4-(5-oxy-(trimethylsilyl)ethylvalerate))benzyl]-L-Isoleucine allyl ester

The aldehyde (16.2 g, 50.2 mmol), isoleucine allyl ester (20.5, 100 mmol) and excess MgSO₄ (~40 g) were 30 stirred in CH₂Cl₂ (75 mL) at r.t. for 3 h. Solids were filtered and volatiles were removed in vacuo to yield the crude imine as a yellow oil. MeOH (200 mL) and HOAc (3 mL) was added and the reaction mixture was cooled to 10°C. NaCNBH₃ (6.1 g, 100 mmol) was added portionwise to the 35 stirred solution. The reaction mixture was allowed to warm to room temperature before being stirred for a further 2 h. Volatiles were removed in vacuo and the resulting residue

diluted with H₂O (100 mL) and extracted with EtOAc (3 x 100 mL). The combined EtOAc extractions were washed with saturated brine (1 x 200 mL) and water (1 x 200 mL) before being dried over MgSO₄. Volatiles were removed in vacuo, and the resulting oil purified by flash chromatography (1:1 hexane EtOAc) to yield a clear colourless oil (20.2 g, 79%). ¹HNMR (CDCl₃): δ 7.24 (d, 2H, J=8.0 Hz, H_{arom}), 6.85 (d, 2H, J = 8.0 Hz, H_{arom}), 5.98 (m, 1H, CH=CH₂), 5.31 (d, 1H, J = 27.2 Hz, CH=CH₂), 5.27 (dd, 1H, J = 13.2 Hz, 1.7 Hz, CH=CH₂), 5.10 (dd, 1H, J = 11.2 Hz, 1.7 Hz, CH=CH₂), 4.65 (m, 2H, PheCH₂N), 4.15 (t, 2H, J= 6.9 Hz, OCH₂), 3.92 (m, 2H, OCH₂), 3.81 (d, 1H, J = 13 Hz, CH₂-CH), 3.60 (d, 1H, J = 13 Hz, CH₂-CH), 3.17 (m, 1H, CH), 2.90 (m, CH₂CHCH₃), 2.35 (m, 2H, CHCH₂CH₃), 1.80 (m, 2H, CH₂CH₂), 1.52 (m, 1H, CHCH₂CH₃), 1.20 (m, 1H, CHCH₂CH₃), 0.95 (t, 2H, J = 6.9 Hz, CH₂Si), 0.92 (d, 3H, J = 7.6 Hz, CH₃CH), 0.90 (t, 3H, J= 7.0 Hz, CH₂CH₃), 0.10 (s, 9H, Si(CH₃)₃); ¹³CNMR (CDCl₃) δ 174.55, 174.25, 158.96 132.66, 131.22, 130.48, 130.48, 119.45, 115.02, 115.02, 68.05 65.92, 65.52, 63.20, 52.36, 38.74, 34.78, 29.39, 29.39, 26.35, 22.34, 18.02, 16.23, 12.13, -0.81; MS [M+H]⁺ = 478.3 (expected 478.3).

Boc-L-Ala-[N-(4-(5-oxy-(trimethylsilyl)ethylvalerate))-benzyl]-L-Isoleucine allyl ester





Exact Mass: 648.38

Mol. Wt.: 648.90

Boc-Ala-OH (2.89 g, 15.0 mmol) was dissolved in CH_2Cl_2 (30 mL), to which was added DAST (4.12 g, 20.0 mmol). After activation for 10-15 min to form the acid fluororide, the mixture was washed with cold (H_2O ,
5 dried over MgSO_4 and the volatiles were removed in vacuo. The acid fluoride was then added immediately to a solution of the amine (4.78 g, 10.0 mmol) and DIEA (2.67 mL, 15 mmol) in THF (20 mL). The reaction was stirred at r.t. for 16 h. EtOAc (100 mL) was added and the reaction mixture
10 was washed with 10% K_2CO_3 solution (2 x 250 mL), brine (1 x 250 mL) and H_2O (1 x 250 mL) before being dried over MgSO_4 . Volatiles were removed in vacuo, and the resulting oil purified by flash chromatography (hexane : diethyl ether, 1:5) to yield a clear colourless oil (2.86 g, 44%) :
15 ^1H NMR (CDCl_3): δ 7.24 (d, 2H, $J=8.0$ Hz, H_{arom}), 6.85 (d, 2H, $J = 8.0$ Hz, H_{arom}), 5.98 (m, 1H, $\text{CH}=\text{CH}_2$), 5.31 (d, 1H, $J = 14.2$ Hz, $\text{CH}=\text{CH}_2$), 5.23 (d, 1H, $J=12.0$ Hz, $\text{CH}=\text{CH}_2$)
4.65 (m, 3H, PheCH_2N , CHCH_3), 4.15 (t, 2H, $J= 6.9$ Hz, OCH_2), 3.92 (m, 2H, OCH_2), 3.81 (d, 1H, $J = 13$ Hz, $\text{CH}_2\text{-CH}$),
20 3.60 (d, 1H, $J = 13$ Hz, $\text{CH}_2\text{-CH}$), 3.17 (m, 1H, CH), 2.90 (m, CH_2CHCH_3), 2.35 (m, 2H, CHCH_2CH_3), 1.80 (m, 2H, CH_2CH_2),
1.52 (m, 1H, CHCH_2CH_3), 1.45 (s, 9H, $\text{C}(\text{CH}_2)_3$), 1.20 (m, 1H, CHCH_2CH_3), 0.95 (t, 2H, $J = 6.9$ Hz, CH_2Si), 0.97 (s, 3H, CH_3), 0.92 (d, 3H, $J = 7.6$ Hz, CH_3CH), 0.90 (t, 3H, $J= 7.0$
25 Hz, CH_2CH_3), 0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$); MS $[\text{M}+\text{H}]^+ = 649.5$ (expected 649.4).



**Boc-L-Ala-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Isoleucine
allyl ester**



Exact Mass: 548.31

Mol. Wt.: 548.67



The ester (2.0 g, 2.82 mmol) was stirred in a solution of THF (20 mL) at r.t. TBAF (3 mL, 1M) was added dropwise and saponification proceeded for 3 h. H₂O (100 mL) and HOAc (3 mL) was added to the reaction mixture. The acid was extracted into EtOAc (3 x 100 mL). The combined EtOAc extractions were washed with saturated brine (1 x 100 mL) and water (1 x 100 mL) before being dried over MgSO₄. Volatiles were removed *in vacuo*, and the resulting oil purified by semi-preparative HPLC (0-60% B over 60 min) to yield the tertiary amide as a colourless oil (2.54 g, 44%): ¹HNMR (CDCl₃): δ 7.22 (d, 2H, J=8.0 Hz, H_{aroma}), 6.80 (d, 2H, J = 8.0 Hz, H_{aroma}), 5.91 (m, 1H, CH=CH₂), 5.21 (d, 1H, J = 14.2 Hz, CH=CH₂), 5.22 (d, 1H, J=11.0 Hz, CH=CH₂), 4.65 (m, 3H, PheCH₂N, CHCH₃), 3.92 (m, 2H, OCH₂), 3.81 (d, 1H, J = 13 Hz, CH₂-CH), 3.60 (d, 1H, J = 13 Hz, CH₂-CH), 3.17 (m, 1H, CH), 2.90 (m, CH₂CHCH₃), 2.35 (m, 2H, CHCH₂CH₃), 1.80 (m, 2H, CH₂CH₂), 1.52 (m, 1H, CHCH₂CH₃), 1.45 (s, 9H, C(CH₃)₃), 1.20 (m, 1H, CHCH₂CH₃), 0.97 (s, 3H, CH₃), 0.92 (d, 3H, J = 7.6 Hz, CH₃CH), 0.90 (t, 3H, J=7.0 Hz, CH₂CH₃); δ MS [M+H]⁺ = 549.1 (expected 549.3).

H-Asn-Ser-Leu-Ala-Ile-Pro-Phe-OH

Exact Mass: 760.41

Mol. Wt.: 760.88

The peptide was synthesised in stepwise fashion by established methods using *in situ* neutralisation/HBTU activation protocols for Boc chemistry.¹³ The Xanthyl protecting group was used for the Asn residue and the Benzyl ether for the Ser residue. Coupling reactions were monitored by quantitative ninhydrin assay and were typically >99.9%. After chain assembly was complete the removal of the allyl protecting group was achieved by the addition of tetrakis(triphenylphosphine) palladium [Pd(PPh₃)₄] (580 mg, 0.5 mmol, 3 molar equiv.) to the resin in a solution of CHCl₃ : HOAc : NMM. Vigorous shaking was initiated and continued for 14 h. The solvent was removed and the residue was washed with a 10% solution of diethyldithiocarbamic acid, sodium salt trihydrate [(C₂H₅)₂N₂CS₂Na.3H₂O] in DMF (2 x 10 mL), DMF (2 x 10 mL) MeOH : CH₂Cl₂, 1: 1 (2 x 10 mL) and CH₂Cl₂ (2 x 10 mL). The N^α-Boc group removed with neat TFA (2 x 1 min treatment) and the peptide was cleaved from resin (200 mg, 0.166 mmol/g) using HF : p-cresol, 11 mL, 10:1, for 1 h at -5°C. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous ether before being dissolved in the HPLC buffer and lyophilized. The peptide H-Asn-Ser-Leu-Ala-Ile-Pro-Phe-OH (20) was purified by semi-preparative HPLC (30-90% B over 60 min) to yield a white powder (25 mg 78%); MS [M+H]⁺ = 761.21 (expected 761.42)

H-Pro-Phe-Asn-Ser-Leu-Ala-Ile-OH


Exact Mass: 760.41

Mol. Wt.: 760.88

5

The peptide was synthesised using a similar procedure to that in the previous experiment above using the precursor Boc-Ala-[Backbone attachment]-Ile-O-Allyl (200 mg, 0.180 mmol/g). The peptide H-Pro-Phe-Asn-Ser-Leu-Ala-Ile was purified by semi-preparative HPLC (30-90% B over 60 min) to yield a white powder (10.5 mg, 39%); MS $[\text{M}+\text{H}]^+ = 761.2$ (expected 761.4).

15

Solution Cyclization**Method 1: Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile)**

Exact Mass: 742.40

Mol. Wt.: 742.86



20

The linear peptide H-Asn-Ser-Leu-Ala-Ile-Pro-Phe-OH (15.0 mg, 0.020 mmol) and BOP (26.1 mg, 0.060 mmol) was

25

stirred in DMF (19.7 mL, 1×10^{-3} M) at -10°C . DIPEA (35 μL , 0.197 mmol) was added dropwise to the solution. After the reaction was left to stir for a further 2 h at this temperature, all volatiles were removed in vacuo. The peptide Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile) was purified by semi-preparative HPLC (30-90% B over 60 min) to yield a white powder (7.0 mg, 48%). $^1\text{H NMR}$ (DMSO): δ MS $[\text{M}+\text{H}]^+ = 743.2$ (expected 743.4092). Also isolated was the dimer, Cyclo-(Asn-Ser-Leu-Ala-Ile-Pro-Phe-Asn-Ser-Leu-Ala-Ile-Pro-Phe) (3 mg, 21%); MS $[\text{M}+\text{H}]^+ = 1486.2$ (expected 1486.8), and the trimer, Cyclo-(Asn-Ser-Leu-Ala-Ile-Pro-Phe-Asn-Ser-Leu-Ala-Ile-Pro-Phe-Asn-Ser-Leu-Ala-Ile-Pro-Phe) (0.7 mg, 5%); MS $[\text{M}+\text{H}]^{2+} = 1115.1$ (expected 1115.1)

15 **Method 2: Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile)**



Exact Mass: 742.40

Mol. Wt.: 742.86



20

The peptide was synthesized using a similar procedure to Method 1 above using H-Pro-Phe-Asn-Ser-Leu-Ala-Ile-OH (100 mg, 0.131 mmol), BOP (174 mg, 0.393 mmol), and DIPEA (228 μL , 1.31 mmol). The peptide cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile) was purified by semi-preparative HPLC (10-70% B over 60 min) to yield a white powder (10.5 mg, 67%); MS $[\text{M}+\text{H}]^+ = 743.2$ (expected 743.4092). All other physical characteristics (^1H NMR, m.p., HPLC retention

time, and amino acid analysis) were also consistent with the results reported for Method 1.

On-Resin Cyclization

5 Method 1: Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile)



Exact Mass: 742.40

Mol. Wt.: 742.86

10

After chain assembly for the linear peptide was complete (synthesised from the solid support where the linker was attached between Boc-Pro-Phe-O-Allyl). The allyl protecting group and the N^α-Boc group was removed with [Pd(PPh₃)₄] (580 mg, 0.5 mmol) and TFA (2 x 1 min treatment) the reaction mixture was then cooled to -10°C and BOP (221 mg, 0.5 mmol) was added. 2,6 Lutidine (194 μL, 1.66 mmol) was then added dropwise and the reaction continued until the ninhydrin assay found an absence of amine <0.1%. The organic material was filtered from the resin (250 mg, 0.167 mmol/g) and the cyclic peptide was cleaved from resin using HF : p-cresol, 11 mL, 10:1, for 1 h at -5°C. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous ether before being dissolved in the HPLC buffer and lyophilized. The peptide Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile) was purified by semi-preparative HPLC (30-90% B over 60 min) to yield a white powder (3.1 mg, 10%): ¹H NMR (DMSO)

15


20

25

δ MS $[M+H]^+ = 743.2$ (expected 743.4092). Also isolated was the dimer, Cyclo-(Asn-Ser-Leu-Ala-Ile-Pro-Phe-Asn-Ser-Leu-Ala-Ile-Pro-Phe) (7.6 mg, 24.5%); MS $[M+H]^+ = 1486.2$ (expected 1486.8), and the trimer, Cyclo-(Asn-Ser-Leu-Ala-Ile-Pro-Phe-Asn-Ser-Leu-Ala-Ile-Pro-Phe) (0.4 mg, 1%); MS $[M+H]^{2+} = 1115.2$ (expected 1115.1). All other physical characteristics (1H NMR, m.p., HPLC retention time, and amino acid analysis) were also consistent with what was reported above.

10

Method 2: Cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile)


 $C_{36}H_{54}N_8O_9$

15

Exact Mass: 742.40


Mol. Wt.: 742.86

The peptide was synthesized using a similar procedure to Method 1 using the precursor where the linker was attached between Boc-Ala-Ile-O-Allyl (200 mg, 0.203 mmol/g), $[Pd(PPh_3)_4]$ (290 mg, 0.250 mmol), BOP (60 mg, 0.136 mmol), and 2,6-lutidine (237 μ L, 2.03 mmol). The peptide cyclo-(Pro-Phe-Asn-Ser-Leu-Ala-Ile) (3) was purified by semi-preparative HPLC (30-90% B over 60 min) to yield a white powder (8.2 mg, 25%); MS $[M+H]^+ = 743.2$ (expected 743.4). All other physical characteristics (1H NMR, m.p., HPLC retention time, and amino acid analysis) were also consistent with what was reported above.

25

Example 10 Fmoc-Based Synthesis Using Linker 8

Similar to linker (7), we have employed linker (8) for the Fmoc-based synthesis of a series of cyclic pentapeptides. The synthesis of the linker is illustrated in Scheme 13, and cyclic products obtained using this linker are listed in Table 7.

10 Reagents and Conditions

- i, $\text{NH}_2(\text{CH}_2)_2\text{CO}_2\text{-Allyl}$, MgCl_2 , THF, r.t. 72 h;
- ii, NaCNBH_3 , CH_3OH , r.t., 2 h;
- iii BOP, Fmoc-Gly-OH, DIEA, DMF, 24 h;
- iv HBTU, DIEA, DMF, 120 min

15

Scheme 13

Table 7
Cyclisation Yields Using Fmoc Backbone Linker

Peptide Sequence	Yield	Reaction
	(%)	Time
cyclo-[Leu-Asp-Val-Gly- β -Ala]	18%	12 h
cyclo-[Arg-Gly-Asp-Gly- β -Ala]	9%	24 h
cyclo-[Phe-Lys-Trp-Gly- β -Ala]	15%	12 h

5

Experimental to Example 11

This section describes the synthetic details for the synthesis of a backbone linker and model peptides using Fmoc chemistry.

10

Synthesis Of Backbone Linker And Model Compounds using Fmoc Chemistry**General Methods**


The fluorenyl-protected amino acids were coupled onto the resin as their free acids (4 mol equiv.) by addition of HBTU (4 mol equiv.) and DIEA (5 mol. equiv.). The couplings were performed in DMF for 20 min. After each successive coupling the resin was rinsed successively with DMF, MeOH and DCM before monitoring the success with Kaiser ninhydrin assay. Removal of the Fmoc group was achieved by treatment (10 min) with 20% piperidine in DMF. Removal of the allyl protecting group was achieved by the addition of Pd(PPh₃)₄ (3 mol equiv.) to the resin in a solution of CHCl₃ : HOAc : NMM, 37:2:1, 5 mL under an atmosphere of nitrogen. Shaking was initiated and continued for 3 h. The resin was rinsed successively with a solution of 10% sodium dithiodicarbonate trihydrate in DMF (twice), DMF, MeOH and DCM, and dried in vacuo.

Linear peptides were removed by TFA (100%) 5 h and checked for purity by HPLC. HPLC was carried out on a Waters apparatus at λ =254 nm on an analytical Vydac column using an isocratic elution with 70% buffer A (H₂O, 0.1%

TFA) for 5 minutes, followed by a 2.5% linear gradient to 80% buffer B (90% CH₃CN, 10% H₂O, 0.1% TFA) at 2 mL/min flow rate. After the final removal of the Fmoc group, the resin was rinsed with DMF before HATU (5 mol equiv.) was added portionwise to the resin in a solution of DMF (2 mL). DIEA (10 mol equiv.) was added dropwise and shaking was initiated and continued for 6 h before a further 5 mol. equiv. HATU and 10 mol. equiv. DIEA was added. Shaking was again recontinued until the resin gave a negative ninhydrin test. The resin was rinsed once again with DMF, MeOH and DCM, and dried in vacuo.

Cyclic peptides were removed by TFA (100%) 5 h and purified by HPLC. HPLC was carried out on a Waters apparatus at $\lambda=214$ nm on a semi-preparative Vydac column using an isocratic elution with 100% buffer A (H₂O, 0.1% TFA) for 10 minutes, followed by a 1% linear gradient to 50% buffer B (90% CH₃CN, 10% H₂O, 0.1% TFA) at 10 mL/min flow rate.

20 **3-Methoxy-4-formylphenol (3)**





Exact Mass: 152.05

25 Mol. Wt.: 152.15

In a 1 L three-necked flask fitted with a dropping funnel, thermometer and drying tube was placed 3-methoxyphenol 5 (70 g, 0.64 mol) and freshly distilled phosphoryl chloride (100 mL, 1.08 mol). The solution was stirred at 0°C whilst DMF (75 mL, 0.97 mol) was added dropwise over 45 min. The solution was further stirred for 24 h before the pale oil was poured onto crushed ice (1 L)

and after 10 min the cloudy solution was washed with ether (2 x 300 mL). The aqueous layer was once again cooled to 0°C and adjusted to pH 5.5-6 by careful addition of NaOH (39 g, 0.98 mol) and then NaOAc (380 g, 4.63 mol). Water (150 mL) and ethyl acetate (EtOAc) (500 mL) were added, and the aqueous layer was washed further with EtOAc (250 mL). The combined organic extracts were washed with brine (250 mL) and water (250 mL), dried over MgSO₄, and evaporated. The residue was triturated with boiling petroleum spirit and the crystalline solid was collected to give the title compound (25.2 g, 27.2%), m.p. 154-5°C [lit m.p.¹² 158.5-160°C]; δ_{H} (d⁶-acetone) 3.08 (1H, br s, OH), 4.92 (2H, s, OCH₃), 6.54 (1H, dd, J 9 Hz, J 2 Hz, 6^{Ar}-H), 6.57 (1H, d, J 2 Hz, 2^{Ar}-H), 7.77 (1H, d, J 9 Hz, 5^{Ar}-H), 10.24 (1H, s, CHO); δ_{C} (d⁶-acetone) 52.76, 99.27, 108.76, 118.63, 130.32, 164.73, 165.29, 187.07.

Methyl 3-methoxy-4-formylphenoxy ethyl ester



Exact Mass: 224.07



Mol. Wt.: 224.21

In a 500 mL flask were added the phenol (24 g, 0.166 mol), methyl bromoacetate (75 g, 0.49 mol) and K₂CO₃ (67.0 g, 0.49 mol) in acetone (100 mL). The reaction mixture was stirred at reflux for 16 h, cooled to room temperature, filtered, and evaporated under reduced pressure. The oily residue was purified by flash column chromatography EtOAc:Hexane (1:3), to give the methyl ester (31.63 g, 85%), m.p. 79-81°C; δ_{H} (CDCl₃) 3.82 (3H, s, OCH₃), 4.82 (2H, s, OCH₂), 4.80 (2H, s, CH₂), 6.48 (1H, dd, J 9 Hz,

\underline{J} 2 Hz, 6^{Ar} -H), 6.57 (1 H, d, \underline{J} 2 Hz, 2^{Ar} -H), 7.80 (1 H, d, \underline{J} 9 Hz, 5^{Ar} -H), 10.29 (1H, s, CHO); δ_c (CDCl₃) 52.45, 55.68, 65.07, 99.24, 105.40, 119.84, 130.76, 163.48, 163.96, 168.46, 188.27.

5

3-Methoxy-4-formylphenoxy acetic acid




10

Exact Mass: 210.05

Mol. Wt.: 210.18

LiOH (0.5 M, 75 mL) was added dropwise to a stirred solution of the methyl ester (7.5 g, 33.45 mmol) in H₂O:THF, 3:2 (100 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for a further 16 h. EtOAc (250 mL) and a Citric acid solution (20%, 500 mL) was added, and the aqueous layer was washed with EtOAc (250 mL). The combined organic extracts were then washed with brine (250 mL) and water (250 mL), dried over MgSO₄, and evaporated to dryness under reduced pressure to give the title compound (6.75 g, 96%), m.p. 106-7°C [lit m.p.¹² 106-7°C]; δ_H (d⁶-acetone) 3.40 (1H, s, OH), 3.82 (3H, s, OCH₃), 3.92 (3H, s, OCH₃), 6.48 (1H, dd, \underline{J} 9 Hz, \underline{J} 2 Hz, 6^{Ar} -H), 6.57 (1 H, d, \underline{J} 2 Hz, 2^{Ar} -H), 7.80 (1 H, d, \underline{J} 9 Hz, 5^{Ar} -H), 10.29 (1H, s, CHO); δ_c (d⁶-acetone) 56.06, 99.01, 106.93, 118.49, 129.80, 163.32, 164.49, 169.57, 187.27.

Allyl 3-amino-[methyl-(2'-methoxy-4'-phenoxy acetic acid)]
propanoic ester



5



 $C_{16}H_{21}NO_6$

Exact Mass: 323.14

Mol. Wt.: 323.34

The aldehyde (1.87 g, 8.92 mmol) and the amine
 10 (2.58 g, 20 mmol) was stirred at room temperature in THF
 (40 mL) in the presence of dry $MgSO_4$ (15 g) for 72 h. The
 reaction mixture was filtered, and evaporated to dryness
 under reduced pressure to give a solid residue. The solid
 was then dissolved in methanol (MeOH) (50 mL) and $NaCNBH_3$
 15 was added portionwise over 10 minutes. The reaction
 mixture was allowed to stir for a further 3 h before ether
 (100 mL) was added. The amino acid was extracted into H_2O
 (3 x 250 mL). Excess $NaCl$ was then added to the H_2O layer
 and the amino acid was extracted back into EtOAc
 20 (3 x 100 mL). The combined organic layers were dried over
 $MgSO_4$, and evaporated to dryness under reduced pressure to
 give the title compound as an unpurified oil (2.59 g, 90%);
 δ_H (d^6 -acetone) 2.95 (2H, t, J 7 Hz, CH_2NH), 3.40 (2H, m,
 CH_2CO), 3.89 (3H, s, OCH_3), 4.22 (2H, m, CH_2O), 4.42 (2H,
 25 s, OCH_2), 5.23 (2H, dd, J 24, J 10 Hz, $CH=CH_2$), 5.91 (1H,
 m, CH), 6.58 (1H, dd, J 9 Hz, J 2 Hz, 6^{Ar} -H), 6.68 (1 H,
 d, J 2 Hz, 2^{Ar} -H), 7.42 (1 H, d, J 9 Hz, 5^{Ar} -H), 8.85 (1H,
 s, OH); δ_C (d^6 -acetone) 43.27, 47.61, 50.10, 64.49, 66.14,
 99.82, 106.30, 112.67, 118.43, 132.97, 133.29, 160.00,
 30 161.67, 170.58, 171.40.

Allyl 3-amino-[carboxymethyl-N-(9'-fluorenylmethoxy-carbonyl)-amino]-[methyl-(2'-methoxy-4'-phenoxy acetic acid)] propanoic ester



Exact Mass: 602.23


Mol. Wt.: 602.63

10 The amino acid (518 mg, 1.6 mmol) was added portionwise to a stirred solution of Fm-Gly-OH (594 mg, 2 mmol), BOP (884 mg, 2 mmol) and DIEA (1 mL) in DMF (5 mL) at r.t. The reaction mixture was allowed to stir for a further 24 h, before being evaporated to dryness under reduced pressure. EtOAc (50 mL) and Citric Acid (10%, 50 mL) were added, and the aqueous layer was washed further with EtOAc (50 mL). The combined organic extratcts was washed with brine (50 mL) and water (50 mL), dried over MgSO₄, and evaporated to dryness under reduced pressure.

15 20 The title compound was purified by HPLC (C-18 reverse phase). HPLC was carried out at $\lambda=254$ nm on a Vydac column using a 1.0% linear gradient from 70% buffer A (H₂O, 0.1% TFA) to 80% buffer B (90% CH₃CN, 10% H₂O, 0.1% TFA) at 20 ml/min flow rate (522 mg, 53%).

25

Cleavage of Fmoc-Gly- β -Ala-O-Allyl from the Acid-Labile Linker



5

 $C_{23}H_{24}N_2O_5$

Exact Mass: 408.17

Mol. Wt. 408.45

Cleavage was performed with 5 mg of the tertiary
10 amide being stirred in TFA (2 mL) for 5 h. The mixture was
evaporated to dryness. HPLC was carried out at $\lambda=254$ nm on
an analytical Vydac column using an isocratic elution 70%
buffer A (H_2O , 0.1% TFA) for 5 minutes followed by a 2.5%
15 linear gradient from to 80% buffer B (90% CH_3CN , 10% H_2O ,
0.1% TFA) at 10 ml/min flow rate. The dipeptide co-eluted
with the known sample and gave the correct molecular ion.



Procedure for the Attachment of the Acid Labile Linker to the Solid Support

20 DIEA (0.49 mL, 2.75 mmol) was added to a solution
of Boc-Gly-OH (43.75 mg, 0.25 mmol), and HBTU (95 mg,
0.25 mmol) in DMF (4mL). This mixture was then added to
Aminomethyl Polystyrene Resin (0.83 mmol/g, 1.0 g).
Shaking was initiated and continued for 20 min before being
25 rinsed with DMF. Pyridine : DMF : Acetic anhydride (Ac_2O)
(1:1:8, 5 mL) was then added and shaking was recontinued
for a further 20 min before being rinsed with excessive
amounts of DMF. Removal of the Boc group was achieved by
treatment with TFA (2 x 1 min). A second Boc-Gly-OH
30 (175 mg, 1.0 mmol) was attached by a similar method [DIEA
(0.49 mL, 2.75 mmol), HBTU (379 mg, 1.0 mmol) in DMF
(4mL)]. Once again removal of the Boc group was achieved
by treatment with TFA (2 x 1 min). Attachment of Allyl

3-amino-[carboxymethyl-N-(9'-fluorenylmethoxycarbonyl)-
amino] - [methyl-(2'-methoxy-4'-phenoxy acetic acid)]
propanoic ester 8 was achieved by the addition of the acid
(301 mg, 0.5 mmol), DIEA (0.27 mL, 1.5 mmol) HBTU (180 mg,
5 0.5 mmol) in DMF (4mL)] to the resin. Shaking was
initiated and continued for 20 min before being rinsed with
DMF, MeOH and dichloromethane (DCM), and dried in vacuo.
After each coupling onto the resin the success of coupling
was monitored with Kaiser ninhydrin assay.

10

Cleavage of Fmoc-Gly- β -Ala-O-Allyl from solid support





15

Exact Mass: 408.17

Mol. Wt.: 408.45

Cleavage was performed with 10 mg of resin being
stirred in TFA (2mL) for 5 h. The mixture was evaporated
20 to dryness under reduced pressure before being taken up in
a solution of H₂O : CH₃CN, (1:1, 5 mL), filtered and then
lyophilised. HPLC was carried out at λ =254 nm on a semi-
preparative Vydac column using an isocratic elution 90%
buffer A (H₂O, 0.1% TFA) for 10 minutes followed by a 1.0%
25 linear gradient from to 70% buffer B (90% CH₃CN, 10% H₂O,
0.1% TFA) at 10 ml/min flow rate.

Cyclo-[Leu-Asp-Val-Gly-β-Ala]





Exact Mass: 455.24

Mol. Wt.: 455.51

5

Cyclo-[Leu-Asp-Val-Gly- β -Ala] was lyophilised to a white powder (12.3 mg, 18%): MS $[M+H]^+ = 456.3$ (456.3);
10 Amino Acid Analysis: Gly = 1.06, β -Ala = 1.01, Asp = 1.03, Val = 1.03, Leu = 0.88.

- Cyclo-[Phe-Trp-Lys-Gly- β -Ala]





Exact Mass: 589.30

Mol. Wt.: 589.69

15

20 Cyclo-[Phe-Trp-Lys-Gly- β -Ala] was lyophilised to a white powder (8.1 mg, 9%): MS $[M+H]^+ = 590.1$ (expected 590.3). Amino Acid Analysis: Gly = 0.99, β -Ala = 1.01, Lys = 1.04, Phe = 1.02, Trp = 0.95.

Cyclo-[Arg-Gly-Asp-Gly-β-Ala]

Excat Mass: 456.21

Mol. Wt.: 456.45

5

Cyclo-[Arg-Gly-Asp-Gly-β-Ala] was lyophilised to a white powder (8.2 mg, 15%): MS $[M+H]^+ = 457.1$ (457.3).

10 Amino Acid Analysis: Gly = 1.95, β-Ala = 1.01, Asp = 0.96, Arg = 1.09.

Example 11 Backbone Linker Plus Ring Contraction:


Application to the synthesis of cyclo - [Ala Pro Leu Phe Ala]


15

As is emphasised below, we have evaluated the combination of the backbone linker and ring contraction approach in the synthesis of cyclo [Ala Pro Leu Phe Ala]. In this instance the peptide was assembled on the backbone linker, and the ring contraction auxiliary appended to the N-terminus through reductive amination. Initial

20 cyclisation and ring contraction were allowed to proceed on resin. The resulting cyclic product was then cleaved off the resin using anhydrous HF.


116



Scheme 14 Reagents and Conditions: I, H-Gly-Leu-Leu- HBTU, DIEA, DMF, r.t.; ii, Ala-OAllyl, NaBH₃CN, 5% HOAc/MeOH, r.t., 3 h; iv, (Boc-Pro)₂-O, DCM, r.t., 16 h; iv, SPPS; v, 2-Hydroxy-4-nitro-benzaldehyde, NaBH₄, DMF, 2 h; vi, Pd(Ph₃)₄, CH₂Cl: HOAc : NMM, 37:2:1, r.t, 3 h; vii DIC, DIEA, 70°C, 2 h; .viii, HF : p-cresol, 10:1, -5 °C, 1- h.

Application to the synthesis of a cyclic tetrapeptide,
10 cyclo[[Hnb]Tyr Arg Phe Gly]

Starting from the attachment of the linker to aminomethyl polystyrene resin **11** (sv = 0.21 mmol/g), reductive amination of the protected amino acid H-Gly-OAllyl using
15 NaCNBH₃ followed by acylation proceeded quantitatively to give **12**. Addition of Boc-Arg(Tos)-OH using standard solid phase peptide protocols gave the linear peptide **13** (Scheme 15).




20

^aReagents: (i) H-Gly-OAllyl, NaCNBH₃, MeOH, rt, 3 h; (ii) Boc-Phe₂-O, DCM, rt, 6 h; (iii) Boc-Arg(Tos)-OH,
25 HBTU, DIEA, DMF.

Scheme 15

118



5 **Reagents:** i TFA : DCM (40:60), 2 x 5 min; ii, Fmoc-Tyr(Boc)-OH, HBTU, DIEA, DMF, 1 h.; iii, piperidine : DMF, 1:1, 2 x 5 min; iv, HnB 2, NaBH₄, DMF, rt, 1 h; v, 3 equiv. Pd(Ph₃)₄, CH₃Cl : HOAc : NMM, 37:2:1, r.t, 3 h; vi HF : p-cresol, 1: 1.

10

Scheme 16


Addition of Fmoc-Tyr(Boc)-OH to 13 using *in situ* neutralisation protocols and HBTU activation resulted in the linear peptide 14 (Scheme 16). Allyl deprotection of 14 using Pd(PPh₃)₄ followed by a final TFA treatment gave the desired linear peptide 15 on resin, while removal of the Fmoc protecting group and reductive amination using HnB and NaBH₄ followed once again by allyl removal gave the desired linear peptide 16.

20

To show purity and ease of synthesis, the peptides were then cleaved (HF : p-cresol, 9:1) to give linear peptides 17 and 18. The HPLC profile of the linear peptides is shown in Figure 8.

25

Cyclisation of the linear peptides **15** and **16** was performed using BOP, DIEA in DMF over 3 days. For linear peptide **15**, without the presence of the [HnB] auxiliary, cyclisation followed by HF cleavage did not produce the desired product. A series of oligomer by-products was detected by both HPLC and LC/MS. The cyclisation of the linear peptide **16**, containing a [HnB] auxiliary, resulted in the desired cyclic product. The reactions are summarised in Scheme 17, and the HPLC profile of the cyclic peptides is shown in Figure 9.




Reagents: i, BOP, DIEA, DMF, r.t. 3h; ii, HF : p-cresol, 1: 1.

Scheme 17

Experimental to Example 11**Synthesis of cyclo [Ala Pro Leu Phe Ala]**

4-(5-Oxyvaleric acid)benzylaldehyde appended to resin 2




5

4-(5-Oxyvaleric acid)benzylaldehyde 1 (0.89 g, 4.0 mmol) and HBTU (1.52 g, 4.0 mmol) was dissolved in DMF (10 mL). DIEA (1 mL) was added to the solution, and this reaction mixture was then added to the precoupled H-Gly-Leu-Leu-aminomethylpolystyrene resin. Substitution value of aminomethylpolystyrene resin (4.8 g, sv=0.21 mmol/g). Shaking was continued for 30 minutes, the eluant filtered off and the resin was washed with DMF (2 x 10 mL), CH₂Cl₂ : MeOH (1: 1, 2 x 10 mL) and CH₂Cl₂ (2 x 10 mL) before being dried.

15

N-[4-(5-oxyvaleric acid)benzyl]-L-Alanine allyl ester appended to resin 3

20




The aldehyde 2 and alanine allyl ester (1.29 g, 10 mmol) was dissolved in 5% HOAc/MeOH (10 mL). The reaction mixture was stirred at room temperature for 5 min before NaBH₃CN (0.61 g, 10 mmol) was added portionwise to the solution. The reaction mixture was allowed to stir for

25

a further 2 h before the eluant was filtered off. The resin was washed with 5% HOAc/MeOH (2 x 10 mL), 5% DIEA/MeOH (3 x 10 mL), CH₂Cl₂ : MeOH (1: 1, 2 x 10 mL) and CH₂Cl₂ (2 x 10 mL) before being dried.

5


Boc-Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester appended to resin 4



10

Boc-Pro-OH (4.31 g, 20.0 mmol) was dissolved in CH₂Cl₂ (10 mL), to which was added diisopropylcarbodiimide DIC (1.26 g, 10.0 mmol). After activation for 10-15 min to form the symmetric anhydride, the mixture was filtered and the filtrate was added to the resin 3. The reaction was shaken at r.t. for 16 h before the eluant was filtered off. The resin was washed with CH₂Cl₂ (5 x 10 mL) before being dried.

20 *H-Ala-Phe-Leu-Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester appended to resin 5*




25

The peptide 5 was synthesised in stepwise fashion by established methods using *in situ* neutralisation/HBtU

activation protocols for Boc chemistry. Coupling reactions were monitored by quantitative ninhydrin assay, and were typically >99.9%.

- 5 *N*-(2-hydroxy-4-nitrobenzyl)-Ala-Phe-Leu-Pro-[*N*-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester appended to resin 6



10

2-Hydroxy 4-nitro-benzaldehyde (1.67 g, 10 mmol) and the peptide on resin 5 was stirred in DMF (4 mL) at r.t. for 5 min. NaBH₄ (0.34 g, 10 mmol) was added portionwise to the solution, and the reaction mixture
 15 allowed to stir for a further 1 h before the eluant was filtered off. The addition of the benzaldehyde and NaBH₄ in DMF (10 mL) was then repeated once. The resin was washed with DMF (3 x 10 mL), CH₂Cl₂ : MeOH (1:1, 2 x 10 mL) and CH₂Cl₂ (2 x 10 mL) before being dried.


20

The allyl protecting group was achieved by the addition of tetrakis(triphenylphosphine) palladium [Pd(PPh₃)₄] (1.74 g, 0.5 mmol) to the resin in a solution of CHCl₃:HOAc:NMM (37:2:1) and continued stirring for 14 h. The solvent was removed and the residue was washed with a
 25 10% solution of diethyldithiocarbamic acid (sodium salt trihydrate [(C₂H₅)₂N₂CS₂Na.3H₂O]) in DMF (2 x 10 mL), then with DMF (2 x 10 mL), MeOH : CH₂Cl₂ 1: 1 (2 x 10 mL) and finally with CH₂Cl₂ (2 x 10 mL).

A small amount of the peptide 7 was cleaved from the resin (100 mg, 0.166 mmol/g) using HF:p-cresol, 5.5 mL, 10:1, for 1 h at -5°C. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous ether, filtered, dissolved in the HPLC buffer and lyophilized. Analytical HPLC (20-70% B over 20 min) showed only one peak; ES-MS M_r 668.4 (calcd 669.3).

Cyclo-[N-(2-hydroxy-4-nitrobenzyl)-Ala-Phe-Leu-Pro-Ala] 10

10



DIC (6.7 mg, 0.04 mmol) was added to a solution of the peptide on resin **7** (200 mg, sv = 0.176 mmol/g) in DMSO (4 mL). DIEA (? mL) was added dropwise to the solution and the reaction mixture was left to stir at r.t. for 1 h before being heated to 70°C for 2 h. The eluant was filtered off and washed with DMF (3 x 10 mL), CH₂Cl₂:MeOH (1:1, 2 x 10 mL) and CH₂Cl₂ (2 x 10 mL) before being dried. The cyclic peptide **10** was cleaved from resin using HF:p-cresol, 5.5 mL, 10:1, for 1h at 0°C. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous ether before being dissolved in the HPLC buffer and lyophilized. Analytical HPLC (20-70% B over 20 min) showed two peaks; a) linear peptide ES-MS M_r 668.4 (calcd 669.3), and cyclized material ES-MS M_r 650.4 (calcd 650.3).

Experimental to the synthesis of a cyclic tetrapeptide
30 cyclo[[Hnb]Tyr Arg Phe Gly]

Peptide Synthesis. All linear peptides were chemically synthesised stepwise using either Fmoc or Boc protecting groups and *in situ* HBTU activation protocols, as previously described by Schnölzer, 1992. Coupling efficiencies were determined by the quantitative ninhydrin test and recoupled where necessary to obtain >99.5% efficiency. Allyl deprotection was performed using 3 equiv. Pd(Ph₃)₄, CH₃Cl : HOAc : NMM, 37:2:1, r.t., 3 h, as previously reported by Kates, 1993.

10

Reductive amination. The selected auxiliary-aldehyde (0.1M) was dissolved in MeOH/DMF (1:1) or DMF/AcOH (100:1) and added to the resin-bound Boc-protected peptide (2 equivalents to resin-bound amine). After 5 min the resin was filtered and a second portion of aldehyde added. After another 5 min the resin was filtered and washed with MeOH/DMF (1:1) or DMF. NaBH₄ (10eq) in MeOH/DMF (1:3) was added and the reaction mixture left standing for 5 min. The resin was again filtered and washed with MeOH/DMF (1:3), DMF, MeOH/DCM (1:1), and air-dried prior to cleavage.

Cleavage. Peptides were cleaved as follows: 250 mg of resin were mixed with 1 mL *p*-cresol and 10 mL HF added at 0°C and the mixture stirred at 0°C for 1 h. After evaporation of the HF the crude product was precipitated and washed with ether (2 x 10 mL). The precipitate was then dissolved in 50% CH₃CN in water (0.095% TFA) for HPLC purification (as above).

H-Tyr-Arg-Phe-Gly-OH 17. The linear peptide was isolated in % yield: ES-MS *Mr* 542.2, calcd for C₂₆H₃₆N₇O₆, 542.3 (monoisotopic).


H-[HnB]Tyr-Arg-Phe-Gly-OH 18. The linear peptide was isolated in % yield: ES-MS *Mr* 693.1, calcd for C₃₃H₄₁N₈O₉, 693.3 (monoisotopic).

Cyclo-[[HnB]Tyr-Arg-Phe-Gly] 22. Cyclisation of H-[HnB]Tyr-Arg-Phe-Gly-OH on backbone linker 18 produced the cyclo-[[HnB]Tyr-Arg-Phe-Gly] in % yield. ES-MS Mr 675.3, calcd for C₃₃H₃₄N₇O₈, 675.3 (monoisotopic).

Example 12 Ring contraction, backbone substitution and backbone linker

Our current backbone linkers can be attached to any atom of the peptide backbone. As the data in Table 3 suggest, more than one N α -substituent results in the best yields of cyclic tetrapeptides for the examples studied. In combination with ring contraction this provides a powerful approach for the synthesis of cyclic peptides.

The peptide outlined below is synthesized using this combined approach. This peptide contains 2 N α -substituents (one is the linker L) and a ring contraction auxiliary. The peptide is cyclised and the purity and yields of products are examined. Reversible N α -substitution in replacement of methylation is also investigated.



$\text{HX} \sim$ = ring contraction auxiliary;
 $\text{X} = \text{O}, \text{S}; \text{L} = \text{backbone linker}$

Example 13 Biological activity of cyclo [Tyr-Arg-Phe-Gly] and cyclo [Tyr-Arg-D-Phe-Gly]

Drugs with opioid receptor binding activity are therapeutically useful for pain relief and for detoxification of opiate addicts, and morphine and naloxone are widely used as analgesics and antidote, respectively. Morphine has undesirable side effects, such as drug

dependency and respiratory depression, and consequently there is a clear medical need for more efficacious drugs with fewer or less severe side effects.

5 Demorphin is a opioid heptapeptide isolated from the skin of South American frogs, and has the following - sequence; (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂). The tetrapeptide analogues (H-Tyr-D-Ala-Phe-Gly-NH-Y) are potent analgesics when administered by
10 intracerebroventricular injection. In Example 3 we synthesised the cyclic tetrapeptides cyclo [Tyr-Arg-Phe-Gly] and cyclo [Tyr-Arg-D-Phe-Gly] designated WP 152 using our combination strategies. Figures 10 and 11 shows the effect of these compounds on the focal extracellular
15 recording of evoked excitatory junction currents (EJC) from visualised sympathetic varicosities, measured as described by (Lavidis (1995)). These results illustrates that the mixture of compounds greatly reduces transmitter release. The effect is reversed by the addition of
20 naloxone, strongly suggesting that one or both of the compounds are potent μ -opiate agonists.

It will be apparent to the person skilled in the art that while the invention has been described in some
25 detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

30

References cited herein are listed on the following pages, and are incorporated herein by this reference.

REFERENCES

- Backes, B.J. and Ellman, J.A.
J. Am. Chem. Soc., 1994 116 11171-11172
- 5 Backes, B.J., Virgilio, A.A. and Ellman, J.A.
J. Am. Chem. Soc., 1996 118 306 55-6
- Bauer, L and Suresh, K.S.
10 J. Org. Chem., 1963 28 1604-1608
- Beusen, D.D., Zabrocki, J., Slomczynska, U., Head, R.D.,
Kao, J.L., and Marshall, G.R.
Biopolymers, 1995 36 181-200
- 15 Botti, P., Pallin, T.D. and Tam, J.P.
J. Am. Chem. Soc., 1996 1996 10018-10024
- Brady, S.F., Paleveda, W.J., Arison, B.H.,
20 Freidinger, R.M., Nutt, R.F. and Veber, D.F.
In Proceedings of the 8th American Peptide Symposium;
Pierce Chemical Company, Rockford: 1983 pp 127
- Camamero, J.A. and Muir, T.W.
25 Chem. Commun., 1997 1369-1370,
- Castro, B., Doromy, J.R., Evin, G. and Selve, C.
Tet. Lett., 1975 14 1219
- 30 Cavelier-Frontin, F., Achmad, S., Verducci, J.,
Jacquier, R., and Pepe, G.
J. Mol. Struc. (Theochem), 1993 286 125
- Ehrlich, A., Heyne, H.-A., Winter, R., Betermann, M.,
35 Haber, H., Carpino, L. and Bienert, M.
J. Org. Chem., 1996 61 8831-8838

Ehrlich, A., Klose, J., Heyne, H., Beyermann, M.,
Carpino, L.A. and Bienert, M.
In Peptides: Chemistry, Structure and Biology; Mayflower
Scientific Ltd: 1996 75-76

5

Flanigan, E. and Marshall, G.R.
Tet. Lett., 1970 27 2403-2406

- 10 Flanigan, E.
"Studies on the solid phase synthesis of cyclic peptides",
PhD Dissertation, Washington University, St Louis, Mo.,
1971,

- 15 Freidinger, R.M., Perlow, D.S. and Veber, D.F.
J. Org. Chem, 1982 59 104-109

- Freudenberg, K., Heel, W.,
20 Chem. Ber. 1953, 86, 190-196

Fridkin, M., Patchornik, A. and Katchalski, E.
J. Am. Chem. Soc., 1965 87 4647-4648

- 25 Fridkin, M., Patchornik, A. and Katchalski, E.
J. Am. Chem. Soc., 1968 90 2953-2957

Fridkin, M., Patchornik, A. and Katchalski, E.
Biochemistry, 1972 11 466-471

30

Heavner, G.A., Audhya, T., Doyle, D., Tjoeng, F.S. and
Goldstein, G.
Int. J. Pept. Prot. Res., 1991 37 198


- 35 Izumiya, N., Kato, T. and Waki, M.
Biopolymers, 1981 20 1785

- Jensen, K.J., Songster, M.F., Vagner, J., Alsina, J.,
Albericio, F. and Barany, G.
In 14th American Peptide Symposium; Mayflower Scientific
Ltd.: 1996 30-32
- 5
Jensen et al
J. Am. Chem. Soc., 1998 120 5441-52
- Kenner, G.W., McDermott, J.R. and Sheppard, R.C.
10 J. Chem. Soc., Chem. Commun., 1971 636-637
- Knorr, R., Trzeciak, A., Bannworth, W., and Gillessen, D.
Tet. Lett., 1989 30 1927
- 15 Laufer, D.A., Chapman, T.M., Marlborough, D.I.,
Vaidya, V.M. and Blout, E.R.
J. Am. Chem. Soc., 1968 90 2696-2698
- Lavidis, N.A.
20 Brit.J. Pharmacol, 1995 116 2852-2859
- Marshall, G.R., Humblet, C., Van Opdenbosch, N. and
Zabrocki, J.
In Peptides: Synthesis, Stucture and Function; Pierce
25 Chemical Co., Rockford, IL: 1981 pp 669-672
- Marshall, D.L. and Liener, I.
J. Org. Chem, 1970 35 867-868
- 30 Moore, M.L.
Internationaal Publication Number WO95/34577, 1995
- Nagai, U. and Sato, K.
Tetrahedron Letters, 1985 26 647-650.
- 35
Osapay, G., Profit, A. and Taylor, J.W.
Tet. Lett., 1990 31 6121.

- Osapay, G. and Taylor, J.W.
J. Am. Chem. Soc., 1990 112 6046
- 5 Osby, J. O., Martin, M. G., Ganem, B.,
Tetrahedron Lett. 1984, 25, 2093-2096
- Richter, L.S., Tom, J.Y.K. and Burnier, J.
10 Tet. Lett., 1994 35 5547-5550
- Rivaille, P., Gautron, J.P., Castro, B. and Milhaud, G.
Tetrahedron, 1980 36 3413-3419.
- 15 Schmidt, R. and Neubert, K.
Int. J. Pept. Prot. Res., 1991 37 502
- Shao, Y., Lu, W. and Kent., S.
Tetrahedron Letters, 1998 39 431-440
- 20 Smythe, M.L. and von Itzstein, M.
J. Am. Chem. Soc., 1994 116 2725-2733
- Zabrocki, J., Dunbar, J.B., Marshall, K.W., Toth, M.V. and
25 Marshall, G.R.
J. Org. Chem., 1992 57 202-209


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of synthesis of a cyclic peptide or peptidomimetic compound of General Formula I



General Formula I

or General Formula II




General Formula II

where L is a linker unit, linking the cyclic peptide to a solid support in which the cycle is a monocycle, bicycle or higher order cycle comprising 1 to 15 monomers, comprising the steps of:

- a) inducing flexibility in the peptide or peptidomimetic compound by reversible *N*-substitution or by forcing a *cis* amide bond conformation using a *cis*-amide bond surrogate to facilitate cyclisation, and, if necessary,
- b) subjecting the cyclic peptide or peptidomimetic compound to a ring contraction reaction.

2. A method according to claim 1, in which the cycle comprises 1 to 10 monomers.

3. A method according to claim 2, in which the cycle comprises 1 to 5 monomers.
4. A method according to any one of claims 1 to 3,
5 in which the cycle is a monocycle.
5. A method according to any one of claims 1 to 3, in which the cycle is a bicycle.
- 10 6. A method according to any one of claims 1 to 3, in which the cycle comprises more than two rings.
7. A method according to any one of claims 1 to 6, in which the compound is of General Formula II, and the
15 linker L is attached to a backbone nitrogen or to an atom in the side chain of the monomer.
8. A method according to any one of claims 1 to 6, which is carried out in solution, comprising the steps of:
20 a) Preparing a linear peptide of General Formula III



25


General Formula III

- where P is a linear peptide of 1 to 15 monomers;
A1 is one or more N-substituents, either reversible or non-reversible, on the peptide backbone, or
30 is a chemical moiety that forces a *cis* conformation of the backbone, and
A2 is a covalently-bonded group of atoms comprising a reactive functionality to form an initial

large cyclic peptide prior to ring contraction to the desired substituted cyclic peptide;

b) Activating the C-terminus to form a cyclic peptide of General Formula IV:


5



General Formula IV

10 c) Permitting the peptide of General Formula IV to rearrange via a ring contraction reaction (which may occur spontaneously) to form a cyclic peptide of General Formula V; and optionally

15



General Formula V


20 d) Subjecting the cyclic peptide of General Formula V to a deprotection reaction to remove the groups A1 and A2 to yield the desired cyclic peptide of General Formula I.

25 9. A method according to claim 8, in which P is a linear peptide of 1 to 10 monomers.

10. A method according to claim 9, in which P is a linear peptide of 1 to 5 monomers.

30

11. A method according to any one of claims 8 to 10, in which A1 and/or A2 is left attached to the peptide.
12. A method according to claim 11, in which A1
5 and/or A2 is subsequently linked to a solid support, derivatised, or linked to another cyclic peptide or peptidomimetic compound.
13. A method according to any one of claims 8 to 12,
10 in which A1 is a reversible N-substituent.
14. A method according to claim 13, in which A1 is a 2-hydroxy-4-methoxybenzyl, 2-hydroxybenzyl or 2-hydroxy-6-nitrobenzyl substituent.
- 15
15. A method according to any one of claims 8 to 10, in which A2 is eliminated by spontaneous ring contraction.
16. A method according to any one of claims 8 to 15,
20 in which A2 comprises a nucleophile that reacts rapidly with a C-terminus to form an initial large ring, which then contracts either spontaneously, or upon heating or additional chemical treatment.
- 25 17. A method according to claim 16, in which A2 is thiol or hydroxyl.
18. A method according to any one of claims 8 to 15, in which A2 is an irreversible substituent, is removed
30 after ring contraction, or is eliminated spontaneously upon ring contraction.
19. A method according to any one of claims 8 to 15, in which A2 is a compound of general formula (a):



(a)


in which the ring

- 5 (a) optionally comprises one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur;
- (b) is of 5 to 7 atoms;
- (c) comprises 3 carbon atoms substituted respectively
- 10 by XH, Z, and Y; and
- (d) is additionally substituted by groups R³ and R⁴ when the compound is a 5-membered ring, or is additionally substituted by groups R³, R⁴, and R⁵ when the compound is a 6-membered ring, or is
- 15 additionally substituted by groups R³, R⁴, R⁵ and R⁶ when the compound is a 7-membered ring,

in which


- X is oxygen, sulphur, CH₂O-, or CH₂S-;
- Y is an electron-withdrawing group;
- 20 Z is any group which allows the formation of a covalent carbon-nitrogen bond; and
- R³, R⁴ and R⁵ are each independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted
- 25 heteroaryl, alkoxy, aryloxy, XH or Y, or a covalent linkage to a solid support, and
- in which R³ and R⁴ or R⁴ and R⁵ can optionally together with the ring form a 5-, 6-, or 7-membered ring.

- 30 20. A method of solid-phase synthesis of a cyclic peptide or peptidomimetic compound of the structure:




5

General Formula II

where L is a linker unit, linking the cyclic peptide to a solid support , comprising the steps of:

- 10 a) synthesis of a linear peptide of General Formula VI, bound to a solid support via a linker L,



15

General Formula VI

in which P is a linear peptide of 1 to 15 monomers, and


- 20 A1 is one or more N-substituents either reversible or non-reversible, on the peptide backbone, or is a chemical moiety that forces a *cis* conformation of the backbone, and

L is a linker between any atom of the peptide and the solid support, and

- 25 (b) either
(i) subjecting the peptide to cyclisation and concomitant cleavage from the solid support to yield a cyclic peptide of General Formula VII,

30


137



General Formula VII

5 followed by selective removal or derivatisation of A1, if necessary followed by side chain deprotection of the peptide and removal of A1 to yield the desired cyclic peptide of General Formula I; or

(ii) cyclisation of the peptide to yield a
10 second solid support bound cyclic peptide of General Formula VIII,



15

General Formula VIII

and subjecting the compound of General Formula VIII to removal of A1 and of any peptide side chain protecting groups, and cleavage from the solid support to yield the
20 desired cyclic peptide of General Formula I.

21. A method according to claim 20, in which the linker L is attached to a backbone nitrogen or a atom in the side chain of the monomer.

25

22. A method according to claim 20 or claim 21, in which the cycle is a monocycle.

23. A method according to claim 20 or claim 21 in which the cycle is a bicycle.


5 24. A method according to claim 20 or claim 21 in which the cycle comprises more than two rings.

25. A method according to any one of claims 20 to 24, in which side chain deprotection of the peptide, removal of
10 A1 and cleavage from the solid support are performed separately.

26. A method according to any one of claims 20 to 24, in which side chain deprotection of the peptide, removal of
15 A1 and cleavage from the resin are performed concurrently.

27. A method of solid-phase synthesis of a cyclic peptide, comprising the steps of:

a) preparing a linear resin-bound peptide of
20 General Formula IX:



General Formula IX


25

where P is a linear peptide of 1 to 15 monomers;
A2 is a covalently-bonded group of atoms
comprising a reactive functionality to form an initial
large cyclic peptide prior to ring contraction to the
30 desired substituted cyclic peptide;

L is a linker between any atom of the peptide and the solid support, and

b) subjecting the peptide of General Formula IX to cyclisation and concomitant cleavage from the resin
35 to yield a cyclic

peptide of General Formula I;




5

General Formula X

c) allowing the cyclic peptide X to undergo ring contraction (which may occur spontaneously) to yield a second cyclic peptide of General Formula XI, and

10




General Formula XI

15

d) either derivatising the group A2, or removing A2 to yield the desired cyclic peptide of General Formula I.

28. A method according to claim 27, in which the linear resin-bound peptide of General Formula IX is subjected to initial cyclisation and ring contraction on the solid support to yield a solid support-bound cyclic peptide of General Formula XII,

25



General Formula XII

and either

(i) cleaved from the solid support to yield an A2- substituted cyclic peptide, or

5 (ii) deprotected and cleaved from the solid support to yield a cyclic peptide of General Formula I.

29. A method according to claim 28, in which A2 is derivatised in solid-phase or in solution.


10

30. A method according to claim 28 or claim 29, in which side chain deprotection of the peptide, removal of A1 and cleavage from the resin are performed separately.

15 31. A method according to claim 28 or claim 29, in which in which side chain deprotection of the peptide, removal of A1 and cleavage from the solid support are performed concurrently.

20 32. A method of solid phase synthesis of a cyclic peptide, comprising the steps of
a) synthesis of a linear solid support-bound peptide of General Formula XIII,

25




General Formula XIII

30 where P is a linear peptide of 1 to 15 monomers;
A1 is one or more N-substituents, either reversible or non-reversible, on the peptide backbone, or is a chemical moiety that forces a cis conformation of the backbone, and

A2 is a covalently-bonded group of atoms comprising a reactive functionality to form an initial large cyclic peptide prior to ring contraction to the desired substituted cyclic peptide;

5 L is a linker between any atom of the peptide and the solid support, and

b) subjecting the peptide of General Formula XIII to cyclisation and concomitant cleavage from the solid support to yield a cyclic peptide of General
10 Formula XIV,



15 General Formula XIV

c) subjecting the cyclic peptide of General Formula XIV to ring contraction (which may be spontaneous), and

20 d) cleaving the groups A1 and A2 to yield the desired cyclic peptide of General Formula I.


33. A method of solid phase synthesis of a cyclic peptide, comprising the steps of;

25 a) synthesis of a linear solid support-bound peptide of General Formula XIII,

b) subjecting the linear peptide to cyclisation on the solid support to yield a cyclic peptide of General Formula XV,


30

142



General Formula XV

- 5 c) subjecting the cyclic peptide to ring contraction (which may occur spontaneously) to yield a cyclic peptide of General Formula XVI,




10

General Formula XVI

and either

- 15 d) cleaving groups A1 and A2 while the peptide is bound to the solid support to yield a resin-bound cyclic peptide of General Formula II, or



20

General Formula II

- e) subjecting the cyclic peptide to deprotection and concomitant cleavage from the solid

support to yield the desired cyclic peptide of General Formula I.

34. A method according to claim 33, in which side
5 chain deprotection of the peptide, removal of A1 and
cleavage from the solid support are performed separately.

35. A method according to claim 33, in which side
chain deprotection of the peptide, removal of A1 and
10 cleavage from the solid support are performed concurrently.

36. A method according to any one of claims 1 to 35,
in which one or more of the monomers carries a side chain
protecting group.

1/11




FIGURE 1

2/11




FIGURE 2




FIGURE 3




FIGURE 4

5/11




FIGURE 5

6/11




FIGURE 6

7/11




FIGURE 7

8/11





FIGURE 8

**FIGURE 9**

10/11




FIGURE 10

**Action of WP152 on Average Amplitude of
Transmitter Release and Its Reversal by Naloxone**





FIGURE 11

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/AU 99/00813

A. CLASSIFICATION OF SUBJECT MATTER		
Int Cl ⁶ : C07K 1/02, 1/04, 1/107, 5/12, 7/64		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07K 1/02, 1/04, 1/107, 5/12, 7/64		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) ORBIT (#keywords: cyclic, cycli:)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Derwent abstract Accession No.93-076437/09, Class B04, WO 9303056 A1 (KOLBECK W.) 18 February 1993	1-36
A	Derwent abstract Accession No.95-404082/51, Class B04, WO 9530694 A1 (ASTRA AB) 16 November 1995	1-36
A	Derwent abstract Accession No.96-279515/29, Class B04, EP 717048 A1 (HOECHST AG) 19 June 1996	1-36
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 1 November 1999		Date of mailing of the international search report - 5 NOV 1999
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  S.R. IDRUS Telephone No.: (02) 6283 2536

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00813

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Derwent abstract Accession No.98-168442/15, Class B04, US 5721210 A (TANABE SEIYAKU CO.) 24 February 1994	1-36

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU 99/00813

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	9303056	AT	166359	AU	24203/92	AU	664855
		DE	69225597	EP	597997	JP	6510028
WO	9530694	AU	24583/95	AU	688040	BR	9507620
		CN	1147819	EP	763062	FI	964443
		HU	9603065	IL	113441	JP	10500404
		NO	964670	NZ	285476	PL	317049
		SE	9401596	SK	1365/96	US	5786447
		ZA	9503315				
EP	717048	AT	171711	AU	40340/95	AU	709360
		CA	2165039	CN	1132210	DE	4444260
		DE	59503776	ES	2124954	JP	8208694
		US	5869447				
US	5721210	CA	2087021	EP	538399	JP	5508860
		US	5192746	WO	9200995		
END OF ANNEX							